JPWO2011083830A1 - Novel anticancer agent and screening method thereof - Google Patents

Abstract

The present invention cultivates a mutant yeast lacking a cell cycle checkpoint factor and a corresponding wild-type yeast into which a nucleic acid encoding a test protein derived from a mammal is introduced, and inhibits the growth of the mutant yeast. A method for screening a cancer treatment target protein, which comprises selecting a test protein that does not inhibit growth as a candidate for a cancer treatment target protein; introducing a nucleic acid encoding the cancer treatment target protein obtained by the method The mutant yeast lacking the cell cycle checkpoint factor is cultured in the presence of the test substance, and the test substance that has recovered the growth of the mutant yeast is selected as a candidate for a substance having anticancer activity. A screening method for a substance having anticancer activity, comprising a dynAP inhibitor having an androstane skeleton, Providing such therapeutic and / or prophylactic agent.

Description

  The present invention relates to a novel anticancer agent and a screening method thereof. More specifically, the present invention relates to a screening method for an anticancer agent using as an index the function inhibition of a dynactin-associated protein (hereinafter sometimes abbreviated as “dynAP”), and the screening method. The present invention relates to a novel anticancer agent having a selected androstane skeleton. Furthermore, another invention relates to a diagnostic agent for cancer comprising an antibody that recognizes a specific region of dynAP.

  Completion of the decoding of the human genome sequence has revealed the existence of many genes that encode proteins whose physiological functions remain unknown. As the simplest eukaryotic cells, yeast cells are widely used for the identification of functions of human proteins and the screening of chemical substances that can be lead compounds for the development of therapeutic drugs. For example, it has been reported that many proteins related to promoting the growth of human cancer cells suppress the growth of yeast (Non-Patent Documents 1-3), and this is used to monitor the recovery of yeast growth. Thus, a high-throughput screening system for anticancer agents has been constructed by selecting human protein inhibitors (Non-patent Document 4). However, wild-type yeast cells have been used exclusively for this kind of screening so far, and no examples using mutant yeast lacking a specific protein have been reported.

  Human C18orf26 protein is a protein of unknown function encoded by a gene on chromosome 18 and has been reported to be expressed in various cancer tissues (Non-patent Document 5).

Biochem. Biophys. Res. Commun., 250: 791-799 (1998) Oncogene, 27: 5431-5442 (2008) Cancer Res., 61: 4175-4183 (2001) Nature Rev. Cancer, 4: 481-492 (2004) Human Protein Atlas data, C18ORF26 expression profiles (http://www.proteinatlas.org/tissue_profile.php?antibody_id=11148&g_no=ENSG0000017869)

The first object of the present invention is to use a mutant yeast deficient in a specific protein and select a novel cancer treatment target that cannot be selected by wild-type yeast by using the growth inhibition of the yeast as an index. Is to provide a screening method for an inhibitor of the cancer treatment target, that is, an anticancer agent, using as an index the growth recovery of the mutant yeast.
The second object of the present invention is to provide a screening method for an anticancer agent using a protein that can be a selected cancer treatment target.
The third object of the present invention is to provide a substance capable of inhibiting the expression or function of a protein that can be a selected cancer treatment target, and an anticancer agent comprising a substance selected by the screening method as an active ingredient. That is.
A fourth object of the present invention is to provide a method for diagnosing cancer and a diagnostic agent therefor, using as an index the expression level of a protein that can be a selected target for cancer treatment or a gene that encodes it.

  In order to achieve the first object, the present inventors used a budding yeast lacking Mad2, which is a component of the spindle assembly checkpoint complex. The spindle assembly checkpoint is checking whether the spindle formation is normal and can be transferred to the late mitotic phase in the late M phase. If spindle formation fails, Mad2 is activated in a centromere-dependent manner that is not associated with microtubules, inhibiting the activity of Cdc20, which is required for the initiation of mitosis, and stopping chromosome division. Loss of the spindle assembly checkpoint for cell division causes chromosomal aneuploidy. Chromosome aneuploidy is widely observed in human solid cancers and is important as a therapeutic target for anticancer drug development [Kops, GJ et al., Nature Reviews Cancer (Nat Rev Cancer, 10, 773 (2005)]. About 10,000 human cDNAs were introduced into the mutant yeast and wild type yeast, respectively, to screen for human cDNAs that inhibit mutant yeast growth but do not inhibit wild type yeast growth. Among them, the present inventors selected a protein encoded by the C18orf26 gene locus that is known to be expressed in various cancer tissues.

  Next, the present inventors screened fungal and bacterial cultures using a Mad2-deficient mutant yeast that overexpresses the C18orf26 gene product in order to obtain compounds that can restore the growth inhibition caused by C18orf26. As a result, a novel compound (3β, 12β, 14β, 16β) -22,23-epoxy-3,12,14, which is an ergostan derivative isolated from the active fraction of the culture solution of Cordyceps fungus Isaria sp. NBRC 104353 , 16-tetrahydroxyergosta-5,7-dien-11-one has been identified as a compound exhibiting a growth recovery action. Therefore, as a result of examining the growth recovery action of analogs of this compound in the same manner, it was found that a compound having a 3-hydroxyandrostan-11-one skeleton can recover the growth of Mad2-deficient mutant yeast. When the effects of these compounds on human cancer cells were examined, compounds showing growth-inhibiting action and apoptosis-inducing action on cancer cells expressing the C18orf26 gene were obtained.

  On the other hand, the present inventors examined the expression of the protein in various cancer cell lines using an antibody that recognizes the vicinity of the N-terminus of the C18orf26 gene product (amino acid sequence at positions 19-32). As a result, it was confirmed that this protein was expressed in about half of the cancer cell lines examined. In addition, we attempted to identify intracellular proteins and interacting proteins using C18orf26 tagged with GFP or FLAG. As a result, this protein is localized in the plasma membrane and the Golgi membrane, and has at least two subunits of the dynactin complex (both p150Glued and dynamitin (dynactin2, p50) that mediate the interaction between microtubules and organelles with the cytoplasmic dynein motor. Called))). Based on this finding, the inventors named the C18orf26 gene product dynactin-associated protein (dynAP).

  In order to elucidate the mechanism of the effect of compounds obtained by screening using yeast on human cancer cells, the present inventors have conducted further studies. As a result, the sensitivity of cancer cells to these compounds depends on the expression level of dynAP. Dependent on the Golgi apparatus, and the fragmentation of the Golgi apparatus prior to apoptosis induced by the compound, and the compound promotes phosphorylation of p150Glued, and depending on the phosphorylation, p150Glued and dynAP Disappearance of the interaction, the compound inhibits Akt expression and phosphorylation, which activates GSK3β, suppresses β-catenin expression, and activates c-Myc gene and cyclin D1 gene transcription. It discovered that it was inhibited etc., and came to complete this invention.

That is, the present invention is as follows.
(1) A mutant yeast lacking a cell cycle checkpoint factor and a corresponding wild-type yeast introduced with a nucleic acid encoding a test protein derived from a mammal are cultured to inhibit the growth of the mutant yeast, but the growth of the wild-type yeast A screening method for a cancer treatment target protein, which comprises selecting a test protein that does not inhibit the expression as a candidate cancer treatment target protein.
(2) The method according to (1) above, wherein the cell cycle checkpoint factor is a spindle assembly checkpoint factor.
(3) The method according to (2) above, wherein the spindle assembly checkpoint factor is Mad2.
(4) The method according to any one of (1) to (3) above, wherein the test protein is involved in the growth of cancer cells.
(5) The method according to any one of (1) to (4) above, wherein the mammal is a human.
(6) The above (1) to (5), further comprising inhibiting the expression or function of the protein in a cancer cell expressing the selected protein and confirming that the growth of the cancer cell is suppressed. The method in any one of.
(7) A mutant yeast lacking a cell cycle checkpoint factor, into which a nucleic acid encoding a cancer treatment target protein obtained by the method according to any one of (1) to (6) above is introduced, is used as a test substance. A screening method for a substance having an anti-cancer activity, comprising selecting a test substance cultured in the presence and restoring the growth of the mutant yeast as a candidate for a substance having an anti-cancer action.
(8) The method according to (7) above, further comprising contacting the selected substance with a cancer cell expressing the protein and confirming that the growth of the cancer cell is suppressed.
(9) The method according to (7) or (8) above, wherein the protein is dynAP.
(10) The method comprises contacting dynAP and a protein constituting the dynactin complex in the presence of a test substance, and selecting a test substance that inhibits the binding of both proteins as a candidate for a substance having anticancer activity. A screening method for a substance having an anticancer activity.
(11) A cell that expresses dynAP and a protein constituting the dynactin complex is brought into contact with a test substance, the binding of both proteins is measured by expression of a reporter gene, and the test substance that inhibits the binding is treated with anticancer activity. A method for screening a substance having anticancer activity, which comprises selecting as a candidate for a substance having an anti-cancer activity.
(12) The method according to (10) or (11) above, wherein the protein constituting the dynactin complex is p150Glued or dynamitin.
(13) An anti-cancer characterized by contacting a cell expressing dynAP and p150Glued with a test substance, and selecting a test substance that promotes phosphorylation of p150Glued as a candidate for a substance having anti-cancer activity A screening method for a substance having an action.
(14) contacting cells expressing dynAP with a test substance, and selecting a test substance that exhibits any of the following actions (a) to (h) as a candidate for a substance having an anticancer action: A screening method for a substance having anticancer activity, which is characterized.
(A) increase the number of cells containing the scattered Golgi apparatus (b) inhibit Akt expression and / or phosphorylation (c) inhibit GSK3β phosphorylation (d) inhibit β-catenin expression ( e) inhibit the expression of one or more genes selected from cyclin D1, c-Myc and E-cadherin (f) increase the protein level of p53 and / or p21 (g) from Mst1, caspase-8 and PARP (H) enhances cleavage of one or more selected proteins (h) attenuates cellular response to serum stimulation (15) cells expressing dynAP contain a reporter gene under the control of the cyclin D1 gene promoter (14 ) Described method.
(16) A therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits expression of dynAP selected from the following (a) to (c).
(A) Antisense nucleic acid against RNA encoding dynAP (b) Ribozyme nucleic acid against RNA encoding dynAP (c) Nucleic acid having RNAi activity against RNA encoding dynAP or precursor thereof (17) A therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits the function of dynAP selected from (b) and (b).
(A) Neutralizing antibody against dynAP (b) Compound that inhibits binding between dynAP and protein constituting dynactin complex (18) The protein constituting dynactin complex is p150Glued or dynamitin according to the above (17) Agent.
(19) The agent according to (17) above, wherein the compound that inhibits the binding between dynAP and the protein constituting the dynactin complex is represented by the following formula (I).

Wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ represent at least one substituent with respect to the ring to which they are attached, and each occurrence independently represents a hydrogen atom, hydroxy group, a halogen, which may have a substituent (C 1 _{-C 6)} alkyl group, which may have a substituent (C 2 _{-C 6)} alkenyl group, which may have a substituent good _(C 3 -C ₆₎ alkynyl group, which may have a substituent _(C 3 -C ₆₎ cycloalkyl group, which may have a substituent _(C 1 -C ₆₎ alkoxy group, An optionally substituted (C ₁ -C ₆ ) alkylthio group, an optionally substituted (C ₁ -C ₆ ) alkylsulfinyl group, an optionally substituted group (C ₁ -C ₆₎ alkylsulfonyl group, an amino group which may have a substituent, a nitro Represents a group, a thiol group or a cyano group;
A solid line and a broken line represent a single bond or a double bond. )
(20) The agent according to (18) above, wherein the compound that inhibits the binding between dynAP and the protein constituting the dynactin complex is represented by the following formula (II).

(In the formula, a solid line and a broken line represent a single bond or a double bond.)
(21) A compound represented by the following formula (III).

(22) A diagnostic agent for cancer expressing dynAP, comprising an antibody that recognizes the N-terminal region of dynAP.
(23) The agent according to any one of (16) to (20), which is used in combination with the diagnostic agent according to (22) above.

  dynAP is useful as a diagnostic marker for cancer and as a drug discovery target for anticancer drugs.

(A) It is a figure which shows that the overexpression of dynAP inhibits the proliferation of a spindle assembly checkpoint factor deletion yeast. dynAP full-length cDNA (dynAP) or empty vector (Vector) is introduced into wild type (WT) and mutant yeast (Δmad1, Δmad2, Δmad3, Δbub3), and the transformants in the logarithmic growth phase are serially diluted 5-fold, Spotted on galactose medium (Gal) or glucose medium (Glu) and incubated for 1-2 days. (B) is a diagram showing the structural formula of a compound (# 1- # 8) for which the growth recovery activity of Mad2 deletion mutant yeast (Δmad2) overexpressing dynAP was tested. (C) It is a figure which shows the growth recovery activity of a compound (# 1- # 8). Δmad2 mutant strain containing full-length dynAP cDNA or empty vector in logarithmic growth phase was incubated in galactose medium containing various concentrations of compound (# 1- # 8) for 48 hours, and then the OD of the culture solution was measured. Thus, the growth recovery activity was calculated. (A) Schematic diagram showing the structure of human dynAP. The transmembrane domain (113-133) and the threonine-rich domain (172-207) are indicated by boxes. “Antigen” indicates the antigenic peptide (19-32) used for the production of the polyclonal antibody. (B) shows the alignment of human dynAP and its monkey, chimpanzee, dog and mouse homologues. (A) Immunoblot analysis using anti-GFP antibody and anti-dynAP antibody of HeLa cells (stable # 1 and # 2) stably expressing GFP-dynAP and control HeLa cell extracts. A band of about 70 kDa corresponds to GFP-dynAP, and a band of about 45 kDa corresponds to endogenous dynAP. (B) It is a figure which shows the result of having investigated the expression of dynAP in various human cells by the immunoblot analysis. The signal intensity of the 45 kDa band was measured using an NIH image, and the relative intensity with respect to the band intensity of α-tubulin was calculated. The numerical value at the bottom of the panel shows the relative value of each cell with the dynAP intensity of ACHN cells being 100%. (C) It is a figure which shows the dynAP mRNA level in various cells. The full length of dynAP cDNA and a part of GAPDH as an internal standard were amplified by RT-PCR. It is a figure which shows that dynAP localizes to a plasma membrane and a Golgi membrane. (A) KMST-6 and HeLa cells stably expressing GFP-dynAP were fixed with methanol. DNA was stained with DAPI (blue). The scale bar indicates 5 μm. (B)-(D) HeLa cells that transiently express GFP-dynAP are fixed with methanol and immunized with anti-GM130 antibody (B), anti-β-tubulin antibody (C), and anti-p150Glued antibody (D). Stained. (E) shows the results of immunoblot analysis of the membrane, nucleus and cytoplasmic fractions of ACHN cells. It is a figure which shows that dynAP couple | bonds with dynactin structural component p150Glued and dynamitin. The extract of ACHN cells was immunoprecipitated (IP) with anti-p150Glued antibody (A), anti-dynamitin antibody (B) or anti-dynAP antibody, and immunoblot analysis was performed with antibodies against each protein. Anti-c-myc antibody (A, B) and preimmune serum (Pre.) Were used as controls. "Total" detected the protein in a cell extract with the antibody with respect to each protein. FIG. 6 shows that dynAP co-immunoprecipitates with p150Glued and dynamitin. Various cell extracts were immunoprecipitated (IP) with anti-dynAP antibodies, and immunoblot analysis was performed with antibodies against each protein. Pre-immune serum (Pre.) Was used as a control. "Total" detected the protein in a cell extract with the antibody with respect to each protein. Although the expression of dynAP in DLD-1 cells is very low, the physical interaction with the dynactin component is clearly observed. (A) Number of viable ACHN cells after 24 hours exposure to 5 μM compound # 1- # 8. The initial cell density at 0 hours is 3.2 × 10 ⁵ cells / ml. Error bars indicate the standard deviation of 3 experiments. (B) Percentage of (sub-G1) ACHN cells undergoing apoptosis after exposure to 5 μM compound # 1- # 4 for 24 hours. (C) Caspase-8 and PARP cleavage in ACHN cells after 24 hours exposure to 5 μM compound # 1- # 8. Full length indicates a native form, and Cleaved indicates a cut form. (D) It is a figure which shows that the sensitivity with respect to the apoptosis induced by compound # 4 changes depending on the dynAP level of a cell. The percentage of apoptotic cells (sub-G1 cell fraction) in ACHN, HeLa and DLD-1 cells after 24 hours exposure to various concentrations of compound # 4 was examined by flow cytometry. (E) Sensitivity to caspase-8 and PARP cleavage induced by compound # 4 varies depending on cellular dynAP level. ACHN, HeLa, and DLD-1 cells were exposed to 5 μM Compound # 4 for 24 hours, and then the cell extract was immunoblot analyzed to detect native and cleaved forms of caspase-8 and PARP, and PARP The cleavage rate was calculated from the signal intensity. It is a figure which shows the ratio (the fraction of a sub-G1 cell) of an apoptotic cell in ACHN cell after exposing to 5 micromol compound # 1- # 4 for 24 hours. At the end of exposure, cells were gently trypsinized and analyzed by flow cytometry. FIG. 4 is a graph showing that apoptotic death of cancer cells induced by compound # 4 depends on dynAP levels. After 24 hours exposure to compound # 4, ACHN, HeLa and DLD-1 cells were gently trypsinized and analyzed by flow cytometry. The ratio of apoptotic cells (sub-G1 cell fraction) is shown. It is a figure which shows that the caspase-8 mediated apoptosis pathway in DLD-1 cell is not defective. Caspase-8 cleavage in DLD-1 cells was monitored after 24 hours exposure to various concentrations of staurosporine. (A) Mst1 cleavage induced by compound # 4 is dependent on dynAP level. After 24 hours exposure to various concentrations of Compound # 4, ACHN, HeLa and DLD-1 cell cell extracts were analyzed by immunoblot to detect cleavage of Mst1. Full length indicates the native Mst1 form, and Cleaved indicates the cleaved Mst1 form. (B) The caspase inhibitor Z-VAD-FMK shows not only caspase-8 and PARP but also the cleavage of Mst1. Extracts of ACHN and HeLa cells exposed to compound # 4 and / or Z-VAD-FMK for 24 hours were immunoblot analyzed to detect cleavage of caspase-8, PARP and Mst1. (C, D) Exogenous dynAP expression promotes caspase-8 (C) and Mst1 (D) cleavage induced by compound # 4. HeLa cells stably expressing GFP-dynAP and control HeLa cells were treated with compound # 4 for 24 hours, and cell extracts were subjected to immunoblot analysis to detect cleavage of caspase-8 (C) and Mst1 (D). (E) It is a figure which shows that the cutting | disconnection of procaspase-8 and Mst1 dependent on compound # 4 is suppressed by shRNA knockdown of dynAP. Cleavage of Mst1, caspase-8 and PARP in cells transfected with shRNA against dynAP or non-specific shRNA was detected by immunoblot analysis. (F) shows that Mst1 cleavage induced by compound # 4 occurs simultaneously with caspase-8 and PARP cleavage. After treating ACHN and HeLa cells with compound # 4, cell extracts were prepared at various times and analyzed by immunoblot to detect caspase-8, PARP and Mst1 cleavage. (A) shows that compounds # 4 and # 8 cause Golgi fragmentation. After exposure to 2.5 μM compound # 1- # 8 for 16 hours, ACHN cells were fixed with methanol and stained with anti-GM130 antibody to examine the percentage of cells containing the Golgi apparatus scattered. (B, C) Golgi fragmentation induced by compound # 4 is different depending on the dynAP level of the cells. ACHN, HeLa and DLD-1 cells were exposed to 2.5 μM compound # 4. The percentage of Golgi fragmentation was examined after 16 hours (B) or every 2 hours (C). (D) Compound # 4 shows that phosphorylation of p150Glued in ACHN cells is induced but not in DLD-1 cells. P150Glued was detected by immunoblotting analysis of ACHN and DLD-1 cell extracts before and after exposure to 25 μM compound # 4 for 24 hours (left). The shift of p150Glued mobility in ACHN cells after treatment with compound # 4 suggests phosphorylation of p150Glued. When the extract of ACHN cells treated with compound # 4 was immunoprecipitated with anti-p150Glued antibody and incubated with λ-protein phosphatase (λ-PPase), the mobility of p150Glued shifted downward, so compound # 4 was p150Glued It was shown to induce phosphorylation of (right). (E) Compound # 4 shows that the interaction between dynAP and p150Glued is attenuated. Extracts of ACHN cells exposed to various concentrations of Compound # 4 for 24 hours were immunoprecipitated with anti-dynAP antibody (middle) or anti-p150Glued antibody (right), and dynAP and p150Glued were detected by immunoblot analysis. “Total” detected dynAP and p150Glued in the cell extract with an antibody against each protein. FIG. 5 shows that compound # 4 induces Golgi fragmentation. The scale bar indicates 5 μm. (A) After exposure to 2.5 μM compound # 1- # 8 for 16 hours, ACHN cells were fixed and stained with anti-GM130 antibody (red). DNA was stained with DAPI (blue). (B) After 16 hours exposure to 2.5 μM compound # 4, ACHN, HeLa and DLD-1 cells were fixed and stained with anti-GM130 antibody (red). DNA was stained with DAPI (blue). FIG. 5 shows that Golgi fragmentation induced by compound # 4 is not affected by the caspase inhibitor Z-VAD-FMK. HeLa cells exposed to compound # 4 and / or Z-VAD-FMK for 10 hours were fixed and stained with anti-GM130 antibody (red). DNA was stained with DAPI (blue) (right panel). The scale bar indicates 5 μm. Cells containing scattered Golgi apparatus were counted (left panel). FIG. 3 is a diagram showing the expression of dynAP in normal fibroblasts and its sensitivity to compound # 4. HUC-fm: umbilical cord fibroblast, WI-38: lung fibroblast, VA-13: WI-38 cell transformed with SV-40. (A) shows dynAP expression in each cell. The relative level was shown with dynAP expression in ACHN cells as 100%. (B) shows caspase-8 cleavage induced by compound # 4. Cells were treated with various concentrations for 24 hours and the extracts were analyzed by immunoblot to detect caspase-8 cleavage. (C, D) shows Golgi fragmentation induced by compound # 4. After 16 hours exposure to 2.5 μM compound # 4, cells were fixed and stained with anti-GM130 antibody (red). DNA was stained with DAPI (blue) (C). The scale bar indicates 5 μm. Cells containing scattered Golgi apparatus were counted (D). (A and B) It is a figure which shows that compound # 4 attenuates cyclin D1 level depending on the dynAP level of a cell. (A) After exposing ACHN, HeLa and DLD-1 cells to 5 or 25 μM compound # 4, the cell extract was immunoblot analyzed to detect cyclin D1. (B) Akt, phosphorylated GSK3β, β-catenin, c-Myc and cyclin D1 levels in HeLa cells exposed to 5 or 25 μM compound # 4 were examined by immunoblot analysis (top). Cyclin D1 mRNA levels in HeLa cells exposed to 5 or 10 μM compound # 4 were examined by RT-PCR (lower panel). (C) Akt level in cells into which full-length Mst1 (Mst1 Full), activated Mst1 (Mst1N), function-deficient Mst1N (mutant in which Lys at position 59 was substituted with Arg; Mst1N KD) or vector alone (Vec) were introduced Were examined by immunoblot analysis. (D) It is a figure which shows that the effect similar to (B) is show | played when it treats with compound # 4 by overexpression of activated Mst1. Immunoblot Akt, phosphorylated GSK3β, β-catenin, c-Myc and cyclin D1 levels in cells transfected with wild-type activated Mst1 (Mst1N WT), function-deficient Mst1N (Mst1N KD) or vector only (Vec) By analysis, the transcription level of cyclin D1 was examined by RT-PCR. (E) Compound # 4-dependent decrease in cyclin D1 level is induced not only by transcriptional repression but also by destabilization of cyclin D1 protein. Levels of introduced cyclin D1 and endogenous cyclin D1 protein in cells overexpressing FLAG-tagged cyclin D1 were examined by immunoblotting and mRNA expression of cyclin D1 by RT-PCR. (F) It is a figure which shows that the protein level of p53 and p21 rises by compound # 4 treatment. Cell extracts exposed to 5 or 25 μM compound # 4 were immunoblot analyzed to detect p53 and p21. (G) It is a figure which shows that the protein level of p21 rises similarly to (F) when it processes by compound # 4 also by overexpression of activated Mst1. The p21 level in cells into which wild type activated Mst1 (Mst1N WT), function-deficient Mst1N (Mst1N KD) or vector alone (Vec) was introduced was examined by immunoblot analysis. (H) It is a figure which shows that transcription | transfer of an E-cadherin gene is suppressed by compound # 4 treatment. The expression of the E-cadherin gene in ACHN and HeLa cells exposed to 5 or 10 μM compound # 4 was examined by RT-PCR. FIG. 4 is a graph showing the effect of dynAP expression and compound # 4 on Akt phosphorylation. (A) Immunoblotting analysis of extracts of HeLa cells expressing GFP-dynAP and control HeLa cells, S473 phosphorylated Akt (pS473) and total Akt (total), T389 phosphorylated S6K (pT389) and total S6K (total ) Was detected. (B) Immunoblot analysis of S473 phosphorylated Akt (pS473) and total Akt (total) levels in normal fibroblast WI-38 and VA-13 cells transformed with SV-40 (expressing dynAP) We investigated by. (C) Immunoblotting analysis of the cell extract obtained by knocking down shRNA of dynAP detected S473 phosphorylated Akt (pS473) and total Akt (total). (D) shows that phosphorylation of Akt is inhibited by treatment with compound # 4. Immunoblotting analysis of S473 phosphorylated Akt (pS473) and total Akt (total) levels in HeLa, ACHN and DLD-1 cells overexpressing GFP-tagged dynAP exposed to 10 μM compound # 4 Examined. An inhibitor of PI3 kinase that controls Akt phosphorylation, LY294002, was used as a control. (E) shows that cleavage of procaspase-8 and Mst1 induced by compound # 4 is dependent on Akt activity. HeLa cells overexpressing Akt were exposed to compound # 4, and the cell extracts were then immunoblot analyzed. (A) It is a figure which shows that bovine serum (FBS) is required for phosphorylation of Akt dependent on dynAP. When cultured for 24 hours in a medium without FBS, dynAP-dependent S473 phosphorylated Akt (pS473) is attenuated and recovered by addition of 10% FBS. (B) dynAP is a diagram showing that the C-terminal protrudes from the cell membrane. HeLa cells expressing dynAP fusion proteins with FLAG and V5 linked to the N-terminus and C-terminus, respectively, were fixed with paraformaldehyde and then permeabilized or not permeabilized. Immunostaining was performed with V5 antibody. (C and D) shows that dynAP shRNA knockdown or exposure to compound # 4 slows cell morphology return after addition of FBS. (C) HeLa cells in which dynAP was knocked down by shRNA were cultured for 24 hours in medium without FBS, 10% FBS was added to the medium, and after 30 minutes, the cells were fixed with methanol, and anti-a-tubulin antibody was used. Immunostained. (D) HeLa cells were cultured in FBS-free medium supplemented with compound # 4 for 24 hours, 10% FBS was added to the medium, and after 30 minutes, the cells were fixed with methanol, anti-a-tubulin, anti-b- Immunostained with actin antibody.

[1] Screening Method for Cancer Treatment Target Protein The present invention provides a novel screening method for cancer treatment target protein using mutant yeast. What are the screening methods for anticancer drugs by monitoring the growth recovery of yeast and selecting an inhibitor of the protein by using the protein related to the promotion of cancer cell growth to suppress the growth of yeast? However, wild-type yeast cells have been exclusively used for these screening systems so far. The present inventors conducted a similar screening using a mutant yeast lacking a cell cycle checkpoint factor, and succeeded in selecting a protein that inhibits the growth of the mutant yeast but does not inhibit the growth of the wild-type yeast. . Therefore, this screening method can provide a novel cancer treatment target that could not be selected by a conventional screening system using wild-type yeast.

The mutant yeast used in the method for screening a cancer treatment target protein of the present invention is not particularly limited as long as it lacks any of cell cycle checkpoint factors. For example, ATR involved in DNA non-replication checkpoints -Mat1, Mad2, Mad3, Bud3, etc. involved in spindle assembly checkpoints, such as -Chk1, ATM / ATR, Chk1 / 2, p53 involved in DNA damage checkpoints, such as Cdc2, Cyclin B, etc. involved in chromosome segregation checkpoints And mutant yeast having a defect in Bax and the like, preferably a yeast lacking a spindle assembly checkpoint factor, and more preferably a yeast lacking Mad2. The species of yeast is also not particularly limited. For example, the genus Saccharomyces (eg, Saccharomyces cerevisiae), Pichia (eg, Pichia pastoris etc.), Criveromyces (eg: Criberomyces lactis), Schizosaccharomyces (eg : Schizosaccharomyces pombe).
These mutant yeasts can be prepared, for example, by destroying the corresponding wild-type yeast target gene by homologous recombination using a drug resistance gene or a gene that complements auxotrophy. For Mad2-deficient mutant yeast, obtain and use mutant yeast prepared from wild-type Saccharomyces cerevisiae BY4742 by the Saccharomyces genome deletion project (www-sequence.stanford.edu/group/yeast_deletion_project/project_desc.html) Can do.

Nucleic acids encoding test proteins introduced into mutant yeast and the corresponding wild-type yeast can be used in mammals (eg, human, mouse, rat, monkey, cow, horse, pig, sheep, goat, dog, cat, rabbit, etc. However, it is preferably a DNA that encodes a protein that is known to be highly expressed in cancer cells. The DNA encoding the test protein may be cDNA or genomic DNA, but is preferably cDNA. The cDNA encoding the test protein can be isolated by a method known per se based on the nucleotide sequence information.
DNA encoding the test protein is inserted into an expression vector that is functional in yeast cells. As the expression vector, for example, a yeast-derived plasmid (eg, pSH19, pSH15) is used. As the promoter, for example, PHO5 promoter, PGK promoter, GAP promoter, ADH promoter and the like can be used.
In addition to the above, an expression vector containing an enhancer, a splicing signal, a poly A addition signal, a selection marker, an SV40 replication origin (hereinafter sometimes abbreviated as SV40ori) and the like is used as desired. it can. Examples of the selection marker include an ampicillin resistance gene (hereinafter sometimes abbreviated as Amp ^r ), a neomycin resistance gene (hereinafter sometimes abbreviated as Neo ^r , G418 resistance) and the like.

Transformation of yeast is, for example, Methods in Enzymology, 194, 182-187 (1991), Proceedings of the National Academy of Sciences of the -It can carry out according to the method as described in USA (Proc. Natl. Acad. Sci. USA), Volume 75, 1929 (1978).
The culture of the transformant can be performed according to a known method depending on the type of the host. The medium used for the culture is preferably a liquid medium, and preferably contains a carbon source, a nitrogen source, an inorganic substance and the like necessary for the growth of the transformant. Examples of the carbon source include glucose, dextrin, soluble starch, and sucrose; examples of the nitrogen source include ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean meal, Inorganic or organic substances such as potato extract; examples of inorganic substances include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, and the like. In addition, yeast extract, vitamins, growth promoting factors and the like may be added to the medium. Suitable media include, for example, Burkholder's minimum media [Bostian, KL et al., Proc. Of the National Academy of Sciences of the USA (Proc. Natl. Acad. Sci. USA), 77, 4505 (1980)] and SD medium containing 0.5% casamino acid [Bitter, GA et al., Proceedings of the National Academy of Sciences of the USA (Proc. Natl. Acad. Sci. USA), 81, 5330 (1984)]. The pH of the medium is preferably about 5-8. The culture is usually performed at about 20 ° C. to 35 ° C. for about 24 to 72 hours. Aeration and agitation may be performed as necessary.

  After completion of the culture, measure and compare the yeast cell density in the culture solution of the mutant yeast and wild type yeast to compare the test protein that inhibits the growth of the mutant yeast but does not inhibit the growth of the wild type yeast. Can be selected as a candidate therapeutic target protein.

  In order to confirm that the selected protein is useful as a cancer treatment target protein, the growth of the cancer cell is suppressed when the expression or function of the protein is inhibited in the cancer cell expressing the protein. Can be tested. Methods for inhibiting the expression or function of the protein include, for example, adding a known inhibitor of the protein, or using a neutralizing antibody against the protein, siRNA against the RNA encoding the protein, an antisense nucleic acid, or the like However, it is not limited to these. As a result of the test, when the growth of cancer cells is suppressed, it can be determined that the protein is useful as a cancer treatment target protein.

  The inventors performed the above screening on approximately 10,000 human cDNAs and succeeded in selecting several proteins that inhibit mutant yeast growth but not wild type yeast growth. Among them, dynAP, which is reported to be expressed in various human cancer cells, was identified as a novel cancer therapeutic target protein.

[2] Screening method for anticancer drug (I)
The present invention also provides a method for screening a substance having an anticancer activity using a mutant yeast lacking a cell cycle checkpoint factor, into which a nucleic acid encoding a cancer treatment target protein obtained by the above method is introduced. provide.
This screening method is characterized in that the yeast is cultured in the presence of a test substance, and a test substance that has recovered the growth of the mutant yeast is selected as a candidate for a substance having anticancer activity. Mutant yeast can be cultured in the same manner as described above.

  Examples of test substances include proteins, peptides, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, etc., and these substances are novel. Alternatively, a known one may be used.

  The contact of the test substance with the yeast cells can be carried out, for example, by adding the test substance to the above medium and culturing the cells for a certain period of time. The concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of, for example, about 0.1 nM to about 100 nM. Examples of the culture time include about 24 hours to about 72 hours.

  As a result of culturing, the density of the yeast cells in the culture medium of the mutant yeast cultured in the presence and absence of the test substance was measured and compared, so that the test substance that recovered the growth of the mutant yeast was It can be selected as a candidate for a substance having cancer action.

  In order to confirm that the selected substance is useful as an anticancer drug, the substance is brought into contact with a cancer cell that expresses the target protein to test whether the growth of the cancer cell is suppressed. be able to. The contact of the substance with cancer cells can be performed by adding the substance to the cancer cell culture medium and culturing the cancer cells for a certain period of time, as in the case of the contact with the yeast cells. it can. The concentration of the substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of about 0.1 nM to about 100 nM, for example. Examples of the culture time include about 24 hours to about 72 hours. As a result of the test, when the growth of cancer cells is suppressed, it can be determined that the protein is useful as a cancer treatment target protein.

As described above, the present inventors have found dynAP as a novel cancer therapeutic target protein. Therefore, a particularly preferred cancer treatment target protein in the method for screening a substance having anticancer activity of the present invention is dynAP.
That is, in a preferred embodiment, a mutant yeast lacking a cell cycle checkpoint factor, preferably a spindle assembly checkpoint factor, particularly preferably Mad2, into which a nucleic acid encoding dynAP has been introduced is cultured in the presence of a test substance. There is provided a screening method for a substance having anticancer activity, which comprises selecting a test substance having recovered the growth of the mutant yeast as a candidate for a substance having anticancer action.

  Preferred examples of the nucleic acid encoding dynAP include human dynAP cDNA (RefSeq Accession No. NM_173629.1) containing the nucleotide sequence represented by SEQ ID NO: 1, or their orthologs in other mammals (eg, mouse ( RefSeq No. AK009098), rat (RefSeq No. XM_001055577.1), chimpanzee (RefSeq No. XM_001134656.1), dog (RefSeq No. XM_848179.1), etc.) and their splice variants, allelic variants, many Examples include cDNA such as molds. Human dynAP cDNA is synthesized, for example, from a cancer cell (eg, ACHN cell) expressing dynAP shown in the Examples based on the nucleotide sequence represented by SEQ ID NO: 1, It can be prepared using conventional methods such as RT-PCR, colony or plaque hybridization.

  Confirmation that the substance selected by screening using a mutant yeast into which a nucleic acid encoding dynAP has been introduced has an anticancer effect is a cancer cell (eg, ACHN cell) that expresses dynAP shown in the Examples. According to the method described above, the substance can be contacted to test whether cancer cell growth is suppressed.

[3] Screening method for anticancer drug (II)
Since dynAP is thought to exert its physiological action by interacting with the protein that constitutes the dynactin complex, substances that inhibit that interaction are anticancer against cancers that express dynAP. Should work. Therefore, the present invention also contacts dynAP and the protein constituting the dynactin complex in the presence of a test substance, and selects a test substance that inhibits the binding of both proteins as a candidate for a substance having anticancer activity. The screening method of the substance which has an anticancer effect | action characterized by the above-mentioned is provided.

dynAP can be isolated from, for example, cancer cells (eg, ACHN cells) expressing dynAP shown in the Examples by a protein separation and purification technique known per se. Alternatively, a yeast cell into which a nucleic acid encoding dynAP used in the screening method for cancer treatment target protein and the screening method for anticancer drug (I) is cultured, and the dynAP protein is recovered from the culture. May be.
Examples of the protein constituting the dynactin complex include p150Glued, dynamitin (p50), p24, and p62, and preferably p150Glued or dynamitin. p150Glued and dynamitin can also be isolated from cancer cells expressing dynAP shown in the examples (for example, ACHN cells) by a known protein separation and purification technique. Alternatively, for example, a transformant obtained by introducing an expression vector containing cDNA encoding human p150Glued (Refseq No. NM_004082.3) and cDNA encoding human dynamitin (Refseq No. NM_006400.3) into an appropriate host. Can also be prepared by culturing and recovering the protein.

  Examples of test substances include proteins, peptides, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, etc., and these substances are novel. Alternatively, a known one may be used.

For example, various buffers (eg, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer) can be used to contact the dynAP and dynactin complex proteins with the test substance. , Acetate buffer, etc.) and the test substance and the protein constituting the dynAP and dynactin complex are added and incubated for a certain period of time. The concentration of the test substance to be added varies depending on the type of compound (solubility, etc.), but is appropriately selected within the range of, for example, about 0.1 to about 100 μg / ml. Examples of the incubation time include about 10 minutes to about 24 hours.
The amount of binding can be measured by, for example, immunoblot analysis using a labeled anti-dynAP antibody and an antibody against the protein constituting the dynactin complex, or labeling either the protein constituting the dynAP or dynactin complex (for example, [ ³ H ], [ ¹²⁵ I], [ ¹⁴ C], [ ³⁵ S], etc.), a gel shift assay, or surface plasmon resonance (SPR).
In the screening method described above, a test substance that inhibits the binding between dynAP and the protein constituting the dynactin complex can be selected as a candidate for a substance having an anticancer effect.

The second aspect of the screening method (II) of the present invention is to measure the degree of binding between dynAP and the protein constituting the dynactin complex using a so-called two-hybrid system with the expression of the reporter gene as an index. It is.
In this embodiment, one of the cDNA encoding dynAP or the cDNA encoding the protein constituting the dynactin complex is included so as to be expressed as a fusion protein with the DNA binding domain (BD) of a transcription factor such as GAL4. An expression vector and an expression vector containing the other cDNA as a fusion protein with a transcription activation domain (AD) of a transcription factor such as VP16 are introduced into a host cell, and the resulting transformant is a test substance. The expression level of the reporter gene in the obtained culture is measured and compared. The host cell carries a reporter gene containing a cis element (BD response element) that can be recognized and bound by BD in the promoter region. The BD fusion protein expressed in the cell binds to the BD response element, but if dynAP interacts with the protein that constitutes the dynactin complex, a hybrid of BD and AD is formed on the BD response element, downstream of it. Transcription of the located reporter gene is activated.
Therefore, if the transcriptional activity of the reporter gene is significantly suppressed in the presence of the test substance compared to the absence, the test substance can be selected as a candidate for a substance having anticancer activity.
As host cells, cells such as humans, monkeys, mice, rats, hamsters, etc., and particularly human-derived cells are preferred. Specifically, COP, L, C127, Sp2 / 0, NS-1, NIH3T3, ST2 and other mouse-derived cells, rat-derived cells, BHK, CHO and other hamster-derived cells, COS1, COS3, COS7, CV1, Vero And host mammalian cells such as monkey-derived cells such as HeLa and 293T. Transformation can be performed by calcium phosphate coprecipitation method, PEG method, electroporation method, microinjection method, lipofection method and the like. For example, the method described in Cell Engineering Supplement 8 New Cell Engineering Experiment Protocol, 263-267 (1995) (published by Shujunsha), Virology, Volume 52, 456 (1973) can be used. Transformed cells include, for example, minimal essential medium (MEM) containing about 5-20% fetal calf serum (Science, 122, 501 (1952)), Dulbecco's modified Eagle medium (DMEM) [Virology, 8, 396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)] Can be cultured. The pH of the medium is preferably about 6-8. Cultivation is usually performed at about 30 to 40 ° C., and aeration and agitation are added as necessary.
In addition, the yeast Two-Hybrid System using yeast as a host cell can also be used.

  As shown in Examples described later, an inhibitor of dynAP phosphorylates p150Glued depending on the intracellular dynAP level, and the interaction between dynAP and p150Glued disappears due to the phosphorylation. Therefore, a candidate for a dynAP inhibitor, that is, a substance having an anticancer activity can be selected using phosphorylation of p150Glued as an index. That is, the present invention is also characterized in that cells expressing dynAP and p150Glued are brought into contact with a test substance, and the test substance that promotes phosphorylation of p150Glued is selected as a candidate for a substance having anticancer activity. A screening method for a substance having anticancer activity is provided.

  Examples of cells that express dynAP and p150Glued include cancer cells (eg, ACHN cells) that express dynAP shown in the Examples. Alternatively, it may be a transformed cell obtained by introducing the cDNA encoding the dynAP and the cDNA encoding the protein constituting the dynactin complex into an appropriate host cell. As host cells, cells such as humans, monkeys, mice, rats, hamsters, etc., and particularly human-derived cells are preferred. Specifically, COP, L, C127, Sp2 / 0, NS-1, NIH3T3, ST2 and other mouse-derived cells, rat-derived cells, BHK, CHO and other hamster-derived cells, COS1, COS3, COS7, CV1, Vero And host mammalian cells such as monkey-derived cells such as HeLa and 293T.

  The contact of the test substance with the above-described cells is, for example, the cell culture medium or various buffer solutions (for example, HEPES buffer, phosphate buffer, phosphate buffered saline, Tris-HCl buffer, borate buffer, acetic acid The test substance can be added to a buffer or the like, and the cells can be incubated for a certain period of time. The concentration of the test substance to be added varies depending on the type of compound (solubility, toxicity, etc.), but is appropriately selected within the range of, for example, about 0.1 nM to about 100 nM. Examples of the incubation time include about 10 minutes to about 24 hours.

Detection of phosphorylation of p150Glued is performed by, for example, immunoblot analysis using a phosphorylated p150Glued-specific antibody, or detection of [ ³² P] -labeled ATP incorporation in a substrate protein by gel electrophoresis and autoradiography. be able to.

In yet another embodiment, a cell expressing dynAP is contacted with a test substance, and a test substance that exhibits any of the following effects (a) to (h) is used as a candidate for a substance having anticancer activity: A screening method for a substance having an anticancer activity, which is characterized by selection, is provided.
(A) increase the number of cells containing the scattered Golgi apparatus (b) inhibit Akt expression and / or phosphorylation (c) inhibit GSK3β phosphorylation (d) inhibit β-catenin expression ( e) inhibit the expression of one or more genes selected from cyclin D1, c-Myc and E-cadherin (f) increase the protein level of p53 and / or p21 (g) from Mst1, caspase-8 and PARP Enhances cleavage of one or more selected proteins (h) attenuates cellular response to serum stimulation

  Examples of cells that express dynAP include cancer cells (eg, ACHN cells) that express dynAP shown in the Examples. Alternatively, it may be a transformed cell obtained by introducing the cDNA encoding dynAP described above into an appropriate host cell. Contact of the test substance with the cells can be performed in the same manner as in the case of using phosphorylation of p150Glued as an index. The cells containing the scattered Golgi apparatus were observed under a microscope, the expression of Akt, β-catenin, cyclin D1, c-Myc, and E-cadherin was determined by RT-PCR and immunoblot analysis. By immunoblotting analysis using an antibody specific for phosphorylated protein, p53 and p21 protein levels, Mst1, caspase-8, and PARP cleavage by immunoblotting analysis, etc. Cultivate in serum-free or low-serum (eg, 0-5%, preferably 0-2%) medium for 6-24 hours in the presence of the test compound, then add serum (eg, 10-20%) and add 10 It can be detected by incubating for -120 minutes and observing changes in cell morphology (eg, examining the localization of α-tubulin and / or β-actin by immunostaining). Alternatively, a reporter gene under the control of the cyclin D1 gene promoter can be introduced into cells that express dynAP, and the expression of the cyclin D1 gene can be evaluated using the expression of the reporter gene as an index.

[4] Therapeutic or preventive agent for cancer expressing dynAP The present invention also provides a therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits the expression of dynAP.
As a substance that specifically inhibits translation from dynAP mRNA to protein (or degrades mRNA), preferably a nucleic acid comprising a base sequence complementary to or substantially complementary to the base sequence of mRNA or a part thereof Is mentioned. The base sequence substantially complementary to the base sequence of mRNA is the extent that it can bind to the target sequence of mRNA and inhibit its translation (or cleave the target sequence) under physiological conditions in mammals. Specifically, for example, with respect to a region that overlaps with a base sequence that is completely complementary to the base sequence of the mRNA (that is, a base sequence of a complementary strand of mRNA), A nucleotide sequence having a homology of 80% or more, preferably about 90% or more, more preferably about 95% or more, particularly preferably about 97% or more.
The “base sequence homology” in the present invention uses the homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool) and the following conditions (expected value = 10; allow gaps; filtering = ON; It can be calculated by match score = 1; mismatch score = -3).

More specifically, the base sequence complementary or substantially complementary to the base sequence of dynAP mRNA is (a) a base complementary or substantially complementary to the base sequence represented by SEQ ID NO: 1. A sequence consisting of (b) a base sequence that hybridizes under stringent conditions with a complementary strand of the base sequence represented by SEQ ID NO: 1, and comprising a protein comprising the amino acid sequence represented by SEQ ID NO: 2 Examples of the sequence that encodes a protein having substantially the same quality of activity and complementary or substantially complementary base sequences.
The stringent conditions are, for example, the conditions described in Current Protocols in Molecular Biology, John Wiley & Sons, 6.3.1-6.3.6, 1999, such as 6 × SSC (sodium chloride / sodium citrate) / 45 ° C. Hybridization, followed by one or more washings at 0.2 × SSC / 0.1% SDS / 50 to 65 ° C., etc., those skilled in the art will be able to determine the hybridization conditions that give the same stringency. It can be selected appropriately.

  “A part of a base sequence complementary or substantially complementary to the base sequence of dynAP mRNA” means that it can specifically bind to the mRNA and inhibits the translation of the protein from the mRNA (or the As long as it can degrade mRNA, its length and position are not particularly limited, but from the viewpoint of sequence specificity, at least 10 bases, preferably at least a portion complementary to or substantially complementary to the target sequence, preferably It contains about 15 bases or more, more preferably about 20 bases or more.

Specifically, the nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of dynAP mRNA or a part thereof is preferably exemplified by any of the following (a) to (c): .
(A) antisense nucleic acid against RNA encoding dynAP (b) ribozyme nucleic acid against RNA encoding dynAP (c) nucleic acid having RNAi activity against RNA encoding dynAP or precursor thereof

(A) Antisense nucleic acid against RNA encoding dynAP “Antisense nucleic acid against RNA encoding dynAP” in the present invention is a base sequence complementary to or substantially complementary to the base sequence of the mRNA or a part thereof. Which has a function of suppressing protein synthesis by forming a specific and stable double strand with the target mRNA and binding thereto.
Antisense nucleic acids are polydeoxyribonucleotides containing 2-deoxy-D-ribose, polyribonucleotides containing D-ribose, other types of polynucleotides that are N-glycosides of purine or pyrimidine bases, Other polymers with non-nucleotide backbones (eg, commercially available protein nucleic acids and synthetic sequence specific nucleic acid polymers) or other polymers containing special linkages, provided that the polymer is a base such as found in DNA or RNA And a nucleotide having a configuration that allows attachment of a base). They may be double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, DNA: RNA hybrids, unmodified polynucleotides (or unmodified oligonucleotides), known modifications Additions, such as those with labels known in the art, capped, methylated, one or more natural nucleotides replaced with analogs, intramolecular nucleotide modifications Such as those having uncharged bonds (eg methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged bonds or sulfur-containing bonds (eg phosphorothioates, phosphorodithioates, etc.) Things such as proteins (eg, nucleases, nuclease inhibitors, toxins, antibodies, signal peptides, poly-L-rigid Having a side chain group such as sugar (eg, monosaccharide), having an intercurrent compound (eg, acridine, psoralen), chelate compound (eg, metal, having radioactivity) It may be one containing a metal, boron, oxidizing metal, etc., one containing an alkylating agent, or one having a modified bond (for example, α-anomeric nucleic acid etc.). Here, the “nucleoside”, “nucleotide” and “nucleic acid” may include not only purine and pyrimidine bases but also those having other modified heterocyclic bases. Such modifications may include methylated purines and pyrimidines, acylated purines and pyrimidines, or other heterocycles. Modified nucleosides and modified nucleotides may also be modified at the sugar moiety, eg, one or more hydroxyl groups are replaced by halogens, aliphatic groups, etc., or functional groups such as ethers, amines, etc. It may have been converted.

  As described above, the antisense nucleic acid may be DNA or RNA, or may be a DNA / RNA chimera. When the antisense nucleic acid is DNA, the RNA: DNA hybrid formed by the target RNA and the antisense DNA can be recognized by the endogenous RNase H and cause selective degradation of the target RNA. Therefore, in the case of antisense DNA directed to degradation by RNase H, the target sequence may be not only the sequence in mRNA but also the sequence of the intron region in the initial translation product of dynAP. The intron sequence can be determined by comparing the genomic sequence and the dynAP cDNA base sequence using a homology search program such as BLAST or FASTA.

  The target region of the antisense nucleic acid of the present invention is not particularly limited in length as long as the antisense nucleic acid hybridizes, and as a result, the translation into the protein is inhibited. MRNA encoding the protein The short sequence may be about 10 bases, and the long sequence may be the entire mRNA or initial transcription product sequence. In view of easiness of synthesis, antigenicity, intracellular migration, and the like, an oligonucleotide consisting of about 10 to about 40 bases, particularly about 15 to about 30 bases is preferable, but not limited thereto.

  Furthermore, the antisense nucleic acid of the present invention not only hybridizes with mRNA and initial transcription products and inhibits translation into proteins, but also binds to these genes, which are double-stranded DNA, to form triplex. It may be one that can form and inhibit transcription to RNA (antigene).

The nucleotide molecule constituting the antisense nucleic acid may be natural DNA or RNA, but various chemicals may be used to improve stability (chemical and / or enzyme) and specific activity (affinity with RNA). Modifications can be included. For example, in order to prevent degradation by a hydrolase such as nuclease, the phosphate residue (phosphate) of each nucleotide constituting the antisense nucleic acid is chemically modified, for example, phosphorothioate (PS), methylphosphonate, phosphorodithionate, etc. It can be substituted with a phosphate residue. In addition, the 2′-position hydroxyl group of the sugar (ribose) of each nucleotide is represented by —OR (R═CH ₃ (2′-O-Me), CH ₂ CH ₂ OCH ₃ (2′-O-MOE), CH ₂ CH ₂ NHC (NH) NH ₂ , CH ₂ CONHCH ₃ , CH ₂ CH ₂ CN, etc.) may be substituted. Furthermore, the base moiety (pyrimidine, purine) may be chemically modified, for example, introduction of a methyl group or a cationic functional group at the 5-position of the pyrimidine base, or substitution of the carbonyl group at the 2-position with thiocarbonyl. Is mentioned.

  The conformation of the sugar part of RNA is dominated by C2'-endo (S type) and C3'-endo (N type). In single-stranded RNA, it exists as an equilibrium between the two, but double-stranded Is fixed to the N type. Therefore, in order to give strong binding ability to the target RNA, BNA (LNA) (Imanishi) is an RNA derivative in which the conformation of the sugar moiety is fixed to N-type by cross-linking 2 'oxygen and 4' carbon. , T. et al., Chem. Commun., 1653-9, 2002; Jepsen, JS et al., Oligonucleotides, 14, 130-46, 2004) and ENA (Morita, K. et al., Nucleosides Nucleotides Nucleicides Nucleic Acids , 22, 1619-21, 2003) can also be preferably used.

  The antisense oligonucleotide of the present invention determines the target sequence of mRNA or initial transcription product based on the dynAP cDNA sequence or genomic DNA sequence, and is a commercially available DNA / RNA automatic synthesizer (Applied Biosystems, Beckman, etc.) ) To synthesize a sequence complementary thereto. In addition, any of the above-described antisense nucleic acids containing various modifications can be chemically synthesized by a method known per se.

(B) Ribozyme nucleic acid against RNA encoding dynAP
Another preferred example of a nucleic acid containing a base sequence complementary to or substantially complementary to the base sequence of dynAP RNA or a part thereof is a ribozyme nucleic acid capable of specifically cleaving the mRNA within the coding region. It is done. “Ribozyme” refers to RNA having an enzyme activity that cleaves nucleic acids in a narrow sense, but in this specification, it is used as a concept including DNA as long as it has sequence-specific nucleic acid cleavage activity. The most versatile ribozyme nucleic acids include self-splicing RNAs found in infectious RNAs such as viroids and virusoids, and hammerhead and hairpin types are known. The hammerhead type exhibits enzyme activity at about 40 bases, and several bases at both ends (about 10 bases in total) adjacent to the part having the hammerhead structure are made complementary to the desired cleavage site of mRNA. By doing so, it is possible to specifically cleave only the target mRNA. This type of ribozyme nucleic acid has the additional advantage of not attacking genomic DNA because it uses only RNA as a substrate.

(C) siRNA or miRNA for RNA encoding dynAP
In the present specification, double-stranded RNA consisting of an oligo RNA complementary to dynAP mRNA and its complementary strand, so-called siRNA, is also complementary or substantially complementary to the nucleotide sequence of dynAP mRNA. Or defined as encompassed by a nucleic acid containing a portion thereof.
The siRNA can be designed based on the cDNA sequence information of the target gene, for example, according to the rules proposed by Elbashir et al. (Genes Dev., 15, 188-200 (2001)). Examples of the target sequence of siRNA include, but are not limited to, AA + (N) ₁₉ , AA + (N) ₂₁ or NA + (N) ₂₁ (N is an arbitrary base). The position of the target sequence is not particularly limited. For the selected target sequence candidate group, whether or not there is homology in the 16-17 base sequence in the non-target mRNA is determined by BLAST (http://www.ncbi.nlm.nih.gov/BLAST/ ) And the like, and the specificity of the selected target sequence is confirmed. For example, when AA + (N) ₁₉ , AA + (N) ₂₁ or NA + (N) ₂₁ (N is an arbitrary base) is used as a target sequence, the target sequence whose specificity has been confirmed is AA (or NA) or later. Two strands consisting of a sense strand having a TT or UU 3 ′ end overhang at 19-21 bases and an antisense strand having a sequence complementary to the 19-21 base and a TT or UU 3 ′ end overhang Strand RNA may be designed as siRNA. In addition, for short hairpin RNA (shRNA) which is a precursor of siRNA, an arbitrary linker sequence (for example, about 5-25 bases) capable of forming a loop structure is appropriately selected, and the sense strand and the antisense strand are combined with each other. It can be designed by linking via a linker sequence.

The sequence of siRNA and / or shRNA can be searched using search software provided free of charge on various websites. Examples of such sites include siRNA Target Finder (http://www.ambion.com/jp/techlib/misc/siRNA_finder.html) and insert design tool for pSilencer ^™ Expression Vector (http: / /www.ambion.com/techlib/misc/psilencer_converter.html), GeneSeer provided by RNAi Codex (http://codex.cshl.edu/scripts/newsearchhairpin.cgi) .

  siRNA is synthesized by each of the sense strand and antisense strand of the target sequence on the mRNA with a DNA / RNA automatic synthesizer, denatured at about 90 to about 95 ° C. for about 1 minute in an appropriate annealing buffer, It can be prepared by annealing at about 30 to about 70 ° C. for about 1 to about 8 hours. Alternatively, it can be prepared by synthesizing a single hairpin RNA (shRNA) serving as a siRNA precursor and cleaving it with a dicer.

Also included herein are nucleic acids that are designed to generate siRNAs against dynAP mRNA in vivo. Examples of such nucleic acids include expression vectors constructed so as to express the above-mentioned shRNA and siRNA. shRNA is an oligo containing a base sequence in which a sense sequence and an antisense strand of a target sequence on mRNA are linked by inserting a spacer sequence (for example, about 5 to 25 bases) long enough to form an appropriate loop structure. It can be prepared by designing RNA and synthesizing it with an automatic DNA / RNA synthesizer. Vectors that express shRNA and siRNA include tandem type and stem loop (hairpin) type. In the former, siRNA sense strand expression cassette and antisense strand expression cassette are linked in tandem, and each strand is expressed and annealed in the cell to form double stranded siRNA (dsRNA). It is. On the other hand, the latter is one in which an shRNA expression cassette is inserted into a vector, in which shRNA is expressed in cells and processed by dicer to form dsRNA. As the promoter, a pol II promoter (for example, a CMV immediate early promoter) can be used, but in order to accurately transcribe a short RNA, a pol III promoter is generally used. Examples of polIII promoters include mouse and human U6-snRNA promoters, human H1-RNase P RNA promoter, and human valine-tRNA promoter. Further, a sequence in which 4 or more Ts are continuous is used as a transcription termination signal.
The siRNA or shRNA expression cassette thus constructed is then inserted into a plasmid vector or viral vector. As such vectors, virus vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, herpes virus, Sendai virus, animal cell expression plasmids and the like are used.

  Nucleic acids containing a base sequence complementary to or substantially complementary to the base sequence of dynAP mRNA or a part thereof are provided in a special form such as a liposome or microsphere, applied to gene therapy, or added. Or can be given in the form In this way, the additional form includes polycationic substances such as polylysine that acts to neutralize the charge of the phosphate group skeleton, lipids that enhance interaction with cell membranes and increase nucleic acid uptake ( Examples include hydrophobic ones such as phospholipid and cholesterol. Preferred lipids for addition include cholesterol and derivatives thereof (eg, cholesteryl chloroformate, cholic acid, etc.). These can be attached to the 3 'or 5' end of nucleic acids and can be attached via bases, sugars, intramolecular nucleoside linkages. Examples of the other group include a cap group specifically arranged at the 3 'end or 5' end of a nucleic acid, which prevents degradation by nucleases such as exonuclease and RNase. Such capping groups include, but are not limited to, hydroxyl protecting groups known in the art, including glycols such as polyethylene glycol and tetraethylene glycol.

  The medicament containing the nucleic acids (a) to (c) is used as a liquid or as a pharmaceutical composition of an appropriate dosage form as a human or non-human mammal (eg, rat, rabbit, sheep, pig, cow, cat). Can be administered orally or parenterally (eg, intravascular administration, subcutaneous administration, etc.).

When the nucleic acid is used as an agent for treating or preventing cancer, it can be formulated and administered according to a method known per se. That is, the nucleic acid of the present invention may be used alone or may be inserted in a functional manner into an appropriate expression vector for mammalian cells such as a retrovirus vector, an adenovirus vector, an adeno-associated virus vector. . The nucleic acid can be administered as it is or together with an auxiliary agent for promoting intake by a catheter such as a gene gun or a hydrogel catheter. Alternatively, it can be aerosolized and locally administered into the trachea as an inhalant.
Furthermore, for the purpose of improving the pharmacokinetics, prolonging the half-life, and improving the efficiency of cellular uptake, the nucleic acid may be formulated (injection) alone or with a carrier such as liposome and administered intravenously, subcutaneously, etc. .

  The nucleic acids (a) to (c) may be administered per se or may be administered as an appropriate pharmaceutical composition. The pharmaceutical composition used for administration may contain the nucleic acid and a pharmacologically acceptable carrier, diluent or excipient. Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.

  As a composition for parenteral administration, for example, injection, suppository, intranasal administration, etc. are used, and the injection is intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, drip injection. You may include dosage forms, such as an agent. Such an injection can be prepared according to a known method. As a method for preparing an injection, it can be prepared by, for example, dissolving, suspending or emulsifying the nucleic acids (a) to (c) in a sterile aqueous liquid or oily liquid usually used for injections. As an aqueous solution for injection, for example, an isotonic solution containing physiological saline, glucose and other adjuvants, and the like are used, and suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, Propylene glycol, polyethylene glycol), nonionic surfactants [eg, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)] and the like may be used in combination. As the oily liquid, for example, sesame oil, soybean oil and the like are used, and benzyl benzoate, benzyl alcohol and the like may be used in combination as a solubilizing agent. The prepared injection solution is preferably filled in a suitable ampoule. Suppositories used for rectal administration may be prepared by mixing the nucleic acid with a normal suppository base.

  Compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like. Such a composition is produced by a known method and may contain a carrier, a diluent or an excipient usually used in the pharmaceutical field. As the carrier and excipient for tablets, for example, lactose, starch, sucrose, and magnesium stearate are used.

  The above parenteral or oral pharmaceutical compositions are conveniently prepared in dosage unit form to suit the dosage of the active ingredient. Examples of the dosage form of such a dosage unit include tablets, pills, capsules, injections (ampoules), and suppositories. It is preferable that the nucleic acids (a) to (c) are usually contained, for example, in an amount of about 0.01 to 500 mg per dosage unit dosage form.

  The dose of the above-mentioned medicament containing the nucleic acids (a) to (c) varies depending on the subject of administration, symptoms, administration route, etc., for example, usually 0.0001 to 20 mg / kg body weight with the nucleic acid as a single dose. It is convenient to administer the degree by intravenous injection about once a day to about 6 months. In the case of other parenteral administration and oral administration, an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.

  The present invention also provides a therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits the function of dynAP.

Specifically, examples of the substance that inhibits the function of dynAP include neutralizing antibodies against dynAP. The antibody may be a polyclonal antibody or a monoclonal antibody. These antibodies can be produced according to per se known antibody or antiserum production methods. The isotype of the antibody is not particularly limited, but preferably IgG, IgM or IgA, particularly preferably IgG. The antibody is not particularly limited as long as it has at least a complementarity determining region (CDR) for specifically recognizing and binding a target antigen. In addition to a complete antibody molecule, for example, Fab, Fab ′, F (ab ') ₂ such as fragments, scFv, scFv-Fc, conjugation molecules prepared by genetic engineering such as minibodies and diabodies, or molecules having a protein stabilizing action such as polyethylene glycol (PEG) They may be modified derivatives thereof. Since dynAP is a single transmembrane membrane protein, preferably a neutralizing antibody against dynAP can recognize the extracellular region of dynAP.

  In a preferred embodiment, since neutralizing antibodies against dynAP are used as pharmaceuticals for human administration, the antibody (preferably a monoclonal antibody) has a reduced risk of showing antigenicity when administered to humans. Antibodies, specifically, fully human antibodies, humanized antibodies, mouse-human chimeric antibodies, etc., particularly preferably fully human antibodies. Humanized antibodies and chimeric antibodies can be produced by genetic engineering according to conventional methods. In addition, a fully human antibody can be produced from a human-human (or mouse) hybridoma, but in order to provide a large amount of antibody stably and at low cost, a human antibody-producing mouse or a phage display method is used. It is desirable to manufacture using.

  The substance that inhibits the function of dynAP is desirably a substance having excellent cell membrane permeability. Therefore, a more preferable substance that inhibits the function of dynAP is a low-molecular compound suitable for Lipinski's Rule that inhibits the binding between dynAP and the protein constituting the dynactin complex. Such a compound can be obtained, for example, using the screening method of the present invention described above.

  Specific examples of the low molecular weight compound that inhibits the binding of dynAP and dynactin complex, preferably p150Glued or dynamitin, include compounds represented by the following formula (I).

Wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ represent at least one substituent with respect to the ring to which they are attached, and each occurrence independently represents a hydrogen atom, hydroxy group, a halogen, which may have a substituent (C 1 _{-C 6)} alkyl group, which may have a substituent (C 2 _{-C 6)} alkenyl group, which may have a substituent good _(C 3 -C ₆₎ alkynyl group, which may have a substituent _(C 3 -C ₆₎ cycloalkyl group, which may have a substituent _(C 1 -C ₆₎ alkoxy group, An optionally substituted (C ₁ -C ₆ ) alkylthio group, an optionally substituted (C ₁ -C ₆ ) alkylsulfinyl group, an optionally substituted group (C ₁ -C ₆₎ alkylsulfonyl group, an amino group which may have a substituent, a nitro Represents a group, a thiol group or a cyano group;
A solid line and a broken line represent a single bond or a double bond. )

  “Halogen” in the present specification includes fluorine, chlorine, bromine and iodine.

Examples of the “(C ₁ -C ₆ ) alkyl group” in the present specification include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, and tert-pentyl. Hexyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like.
Examples of the “(C ₂ -C ₆ ) alkenyl group” in the present specification include vinyl, allyl, propenyl, isopropenyl, but-3-en-1-yl, penta-4-en-1-yl, And hexa-5-en-1-yl.
Examples of the “(C ₂ -C ₆ ) alkynyl group” in the present specification include ethynyl, prop-2-yn-1-yl, but-3-yn-1-yl, and penta-4-in-1 -Yl, hex-5-in-1-yl and the like.
Examples of the “(C ₃ -C ₆ ) cycloalkyl group” in the present specification include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
Examples of the “(C ₁ -C ₆ ) alkoxy group” in the present specification include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neo Pentyloxy, tert-pentyloxy, hexyloxy, 2-ethylbutoxy and the like can be mentioned.
Examples of the “(C ₁ -C ₆ ) alkylthio group” in the present specification include methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio and the like.
Examples of the “(C ₁ -C ₆ ) alkylsulfinyl group” in the present specification include methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and the like. .
Examples of the “(C ₁ -C ₆ ) alkylsulfonyl group” in the present specification include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and the like. .

In the "optionally substituted (C 1 _{-C 6)} alkyl group" in the present specification, "(C 1 _{-C 6)} alkyl group" which may have a "substituent (C "in ₂ -C ₆₎ alkenyl group" _(C 2 -C ₆₎ alkenyl group "," in the "optionally substituted _(C 3 -C ₆₎ alkynyl group" _(C 3 _-C 6) “(C ₃ -C ₆ ) cycloalkyl group” in “alkynyl group” and “optionally substituted (C ₃ -C ₆ ) cycloalkyl group”, “optionally substituted ( “(C ₁ -C ₆ ) alkoxy group” in “C ₁ -C ₆ ) alkoxy group”, “(C ₁ -C ₆ ) alkylthio group optionally having substituent (s)” ((C ₁ -C ₆₎ ) Alkylthio group ”,“ (C ₁ -C ₆ ) alkyl optionally having substituent (s) ” _"(C 1 -C ₆₎ alkyl sulfates in sulfinyl group" sulfinyl group ", and""in which may have a substituent _(C 1 -C ₆₎ alkylsulfonyl group" _(C 1 -C ₆₎ alkylsulfonyl The “group” may have 1 to 5, preferably 1 to 3, substituents at substitutable positions.
As such a substituent, for example,
(1) halogen,
(2) a hydroxy group,
(3) an amino group,
(4) Nitro group,
(5) a cyano group,
(6) an imino group optionally having a substituent,
(7) may have a substituent _(C 1 -C ₃₎ alkylidene group,
(8) an optionally halogenated (C ₁ -C ₆ ) alkoxy group,
_{(9) (C 3 -C 6} ) cycloalkyl group,
_{(10) (C 6 -C 14} ) aryloxy group,
_{(11) (C 7 -C 16} ) aralkyloxy group,
_{(12) (C 1 -C 6} ) alkylamino group,
(13) a di (C ₁ -C ₆ ) alkylamino group,
_{(14) (C 6 -C 14} ) arylamino group,
(15) di _(C 6 _{-C 14)} aryl group,
_{(16) (C 7 -C 16} ) aralkylamino group,
(17) di _(C 7 _{-C 16)} aralkylamino group,
_{(18) N- (C 1 -C} 6) alkyl _-N- (C 6 _{-C 14)} arylamino group,
_{(19) N- (C 1 -C} 6) alkyl _-N- (C 7 _{-C 16)} aralkylamino group,
_{(20) (C 1 -C 6} ) alkyl - carbonyl amino group,
_{(21) (C 1 -C 6} ) alkylthio group,
_{(22) (C 1 -C 6} ) alkylsulfinyl group,
_{(23) (C 1 -C 6} ) alkylsulfonyl group,
_{(24) (C 1 -C 6} ) alkylsulfonyloxy group,
(25) an optionally esterified carboxy group,
(26) an optionally substituted (C ₁ -C ₆ ) alkyl-carbonyl group,
_{(27) (C 1 -C 6} ) alkyl - carbonyl group,
_{(28) (C 3 -C 10} ) cycloalkyl - carbonyl group,
(29) an optionally substituted (C ₆ -C ₁₄ ) aryl-carbonyl group,
_{(30) (C 7 -C 16} ) aralkyl - carbonyl group,
_{(31) (C 1 -C 6} ) alkoxy - carbonyl group,
(32) Heterocycle-carbonyl group,
(33) a carbamoyl group,
(34) a thiocarbamoyl group,
_{(35) (C 1 -C 6} ) alkyl - carbamoyl group,
(36) di _(C 1 -C ₆₎ alkyl - carbamoyl group,
(37) a (C ₆ -C ₁₄ ) aryl-carbamoyl group optionally substituted by 1 to 3 (C ₁ -C ₆ ) alkoxy groups,
(38) di _(C 6 _{-C 14)} aryl - carbamoyl group,
(39) a sulfamoyl group,
_{(40) (C 1 -C 6} ) alkylsulfamoyl group,
(41) a di (C ₁ -C ₆ ) alkylsulfamoyl group,
_{(42) (C 6 -C 14} ) aryl sulfamoyl group,
(43) di _(C 6 _{-C 14)} aryl sulfamoyl group,
_{(44) (C 1 -C 6} ) alkyl group,
The group which consists of etc. is mentioned.

As the “imino group which may have a substituent”, for example,
(1) a hydroxy group; or (2) (i) a carboxy group,
(ii) a (C ₆ -C ₁₄ ) aryl group (eg, phenyl),
(iii) a (C ₁ -C ₆ ) alkoxy-carbonyl group (eg, ethoxycarbonyl), and
(iv) (C ₁ -C ₃ ) alkylidene group (eg, methylidene)
An (C ₁ -C ₆ ) alkoxy group (eg, methoxy, ethoxy, isopropyloxy) optionally substituted with 1 to 3 substituents selected from the group consisting of:
And an imino group which may be substituted with.

The _"(C 1 -C ₃₎ alkylidene group" of "optionally substituted _(C 1 -C ₃₎ alkylidene group", for example, methylidene _(CH 2 =), ethylidene _(CH 3 CH = ) And propylidene (CH ₃ CH ₂ CH =).
The “(C ₁ -C ₃ ) alkylidene group” may have 1 to 3 substituents at substitutable positions. Examples of such a substituent include a carboxy group which may be esterified.

The “(C ₁ -C ₆ ) alkyl-carbonyl group” in the “(C ₁ -C ₆ ) alkyl-carbonyl group optionally having substituent (s)” has 1 to 5 substituents, preferably It may have 1 to 3 substituents. As such a substituent, for example,
(1) halogen;
(2) a hydroxy group;
(3) (i) halogen (eg, fluorine),
(Ii) a hydroxy group,
_{(Iii) (C} 3 -C ₆₎ cycloalkyl group (e.g., cyclopropyl), and (iv) di _(C 1 -C ₆₎ alkylamino group (e.g., dimethylamino),
(C ₁ -C ₆ ) alkoxy group optionally substituted by 1 to 3 substituents selected from the group consisting of:
(4) amino group;
(5) a (C ₁ -C ₆ ) alkylamino group;
(6) a di (C ₁ -C ₆ ) alkylamino group;
(7) a (C ₁ -C ₆ ) alkylthio group;
_{(8) (C 1 -C 6} ) alkylsulfonyl group;
_{(9) (C 3 -C 6} ) cycloalkyl group;
(10) a (C ₁ -C ₆ ) alkyl-carbonyl group;
(11) a (C ₁ -C ₆ ) alkyl-carbonyloxy group;
(12) an optionally esterified carboxy group;
Etc.

The “(C ₆ -C ₁₄ ) aryl-carbonyl group” of the “(C ₆ -C ₁₄ ) aryl-carbonyl group optionally having substituent (s)” is 1 to 5 at the substitutable position, preferably It may have 1 to 3 substituents. As such a substituent, for example,
(1) halogen (eg, fluorine);
(2) a hydroxy group;
(3) an optionally halogenated (C ₁ -C ₆ ) alkyl group;
(4) (i) halogen (eg, F),
(Ii) a hydroxy group,
_{(Iii) (C} 3 -C ₆₎ cycloalkyl group (e.g., cyclopropyl), and (iv) di _(C 1 -C ₆₎ alkylamino group (e.g., dimethylamino)
(C ₁ -C ₆ ) alkoxy group optionally substituted by 1 to 3 substituents selected from the group consisting of:
(5) amino group;
_{(6) (C 1 -C 6} ) alkylamino group;
(7) a di (C ₁ -C ₆ ) alkylamino group;
_{(8) (C 1 -C 6} ) alkylthio group;
(9) (C ₁ -C ₆ ) alkylsulfonyl group;
_{(10) (C 3 -C 6} ) cycloalkyl group;
(11) a (C ₁ -C ₆ ) alkyl-carbonyl group;
(12) (C ₁ -C ₆ ) alkyl-carbonyloxy group;
(13) an optionally esterified carboxy group;
Etc.

  Preferably, the compound that inhibits the binding between dynAP and the protein constituting the dynactin complex is represented by the following formula (II).

(In the formula, a solid line and a broken line represent a single bond or a double bond.)

  The present invention also provides a novel compound represented by the following formula (III).

  The compound is, for example, Cordyceps fungus Isaria sp. NBRC 104353 (National Institute of Technology and Evaluation (NITE) Biotechnology Headquarters, Biogenetic Resource Division (NBRC), 2-5 Kazusa Kamashichi, Kisarazu City, Chiba Prefecture Can be purchased and purchased from the culture extract of -8) using as an index the recovery activity of inhibition of growth of yeast cells due to overexpression of dynAP.

  The compound represented by the formula (I) may be a free form or a salt form. Examples of the salt of the compound include pharmacologically acceptable salts such as trifluoroacetic acid, acetic acid, lactic acid, succinic acid, maleic acid, tartaric acid, citric acid, gluconic acid, ascorbic acid, benzoic acid, Acid addition salts with acids such as methanesulfonic acid, p-toluenesulfonic acid, cinnamic acid, fumaric acid, phosphonic acid, hydrochloric acid, nitric acid, hydrobromic acid, hydroiodic acid, sulfamic acid, sulfuric acid; Metal salts such as potassium, magnesium and calcium; for example, salts with organic bases such as trimethylamine, triethylamine, pyridine, picoline, N-methylpyrrolidine, N-methylpiperidine and N-methylmorpholine.

  The compound represented by formula (I) (also referred to as compound (I)) may be in the form of a prodrug. The prodrug of the compound (I) is a compound that is converted to the compound (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in vivo, that is, the compound (I) that is enzymatically oxidized, reduced, hydrolyzed, etc. ), A compound that undergoes hydrolysis or the like due to gastric acid or the like and changes to compound (I). Compound (I) prodrugs include compounds in which the amino group of compound (I) is acylated, alkylated or phosphorylated (for example, the amino group of compound (I) is eicosanoylated, alanylated, pentylaminocarbonylated) , (5-methyl-2-oxo-1,3-dioxol-4-yl) methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, pivaloyloxymethylation or tert-butylated compounds, etc.) Compounds in which the hydroxyl group of compound (I) is acylated, alkylated, phosphorylated or borated (for example, the hydroxyl group of compound (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanyl Compound or dimethylaminomethylcarbonylated compound) or compound Compounds in which the carboxy group of (I) is esterified or amidated (for example, the carboxy group of compound (I) is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl Esterification, ethoxycarbonyloxyethyl esterification, phthalidyl esterification, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl esterification, cyclohexyloxycarbonylethyl esterification or methylamidated compounds Etc.). These compounds can be produced from compound (I) by a method known per se.

  In addition, the prodrug of compound (I) is a compound that changes to compound (I) under physiological conditions as described in Hirokawa Shoten 1990, “Drug Development”, Volume 7, Molecular Design, pages 163 to 198. It may be.

  When compound (I) has an isomer such as an optical isomer, a stereoisomer, a positional isomer, or a rotational isomer, any one isomer or a mixture of isomers is included in compound (I). Is done. For example, when compound (I) has an optical isomer, the optical isomer resolved from the racemate is also encompassed in compound (I). Each of these isomers can be obtained as a single product by a known synthesis method or separation method (concentration, solvent extraction, column chromatography, recrystallization, etc.).

  Compound (I) may be crystalline or amorphous. When the compound (I) is a crystal, it is included in the compound (I) regardless of whether it is a single crystal form or a mixture of crystal forms. The crystal can be produced by crystallization by applying a crystallization method known per se.

  Compound (I) may be a solvate (such as a hydrate) or a non-solvate, and both are encompassed in compound (I).

Compound (I) may be labeled with an isotope (eg, ³ H, ¹⁴ C, ³⁵ S, ¹²⁵ I, etc.).

  Compound (I) can be produced, for example, by a known organic synthesis method using a commercially available compound shown in FIG. 1 as a raw material.

  A pharmaceutical composition containing a neutralizing antibody against dynAP or a protein constituting dynAP and dynactin complex, preferably a low molecular weight compound that inhibits the binding of p150Glued or dynamitin, can be used as a liquid or as a pharmaceutical composition of an appropriate dosage form. As an oral or parenteral (eg, intravascular, subcutaneous) administration to a human or mammal (eg, rat, rabbit, sheep, pig, cow, cat, dog, monkey, etc.) Can do.

  The above-described antibodies and low-molecular compounds may be administered per se, or may be administered as an appropriate pharmaceutical composition. The pharmaceutical composition used for administration may contain the above antibody or low molecular compound or a salt thereof and a pharmacologically acceptable carrier, diluent or excipient. Such pharmaceutical compositions are provided as dosage forms suitable for oral or parenteral administration.

  As a composition for parenteral administration, for example, injection, suppository, intranasal administration, etc. are used, and the injection is intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, drip injection. You may include dosage forms, such as an agent. Such an injection can be prepared according to a known method. As a method for preparing an injection, it can be prepared by, for example, dissolving, suspending or emulsifying the antibody or low molecular compound of the present invention or a salt thereof in a sterile aqueous liquid or oily liquid usually used for injection. As an aqueous solution for injection, for example, an isotonic solution containing physiological saline, glucose and other adjuvants, and the like are used, and suitable solubilizers such as alcohol (eg, ethanol), polyalcohol (eg, Propylene glycol, polyethylene glycol), nonionic surfactants [eg, polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)] and the like may be used in combination. As the oily liquid, for example, sesame oil, soybean oil and the like are used, and benzyl benzoate, benzyl alcohol and the like may be used in combination as a solubilizing agent. The prepared injection solution is preferably filled in a suitable ampoule. A suppository used for rectal administration may be prepared by mixing the above-mentioned antibody or low molecular weight compound or a salt thereof with an ordinary suppository base.

  Compositions for oral administration include solid or liquid dosage forms, specifically tablets (including dragees and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups Agents, emulsions, suspensions and the like. Such a composition is produced by a known method and may contain a carrier, a diluent or an excipient usually used in the pharmaceutical field. As the carrier and excipient for tablets, for example, lactose, starch, sucrose, and magnesium stearate are used.

  The above parenteral or oral pharmaceutical compositions are conveniently prepared in dosage unit form to suit the dosage of the active ingredient. Examples of the dosage form of such a dosage unit include tablets, pills, capsules, injections (ampoules), and suppositories. The antibody or low molecular weight compound is preferably contained in an amount of usually 0.1 to 500 mg per dosage unit form, especially 5 to 100 mg for injections and 10 to 250 mg for other dosage forms.

  The dose of the above-mentioned medicament containing the above-mentioned antibody or low-molecular compound or a salt thereof varies depending on the administration subject, symptoms, administration route, etc., for example, usually 0.0001 to 20 mg per antibody or low-molecular compound as a single dose It is convenient to administer by intravenous injection about 1 kg / kg body weight, 1 to 5 times a day for low molecular weight compounds, orally or parenterally, and once a day to several months for antibodies. In the case of other parenteral administration and oral administration, an equivalent amount can be administered. If symptoms are particularly severe, the dose may be increased according to the symptoms.

[5] Cancer diagnostic agent / diagnosis method The present invention also provides a diagnostic agent for cancer expressing dynAP, comprising an antibody that recognizes the N-terminal region of dynAP. Antibodies that recognize the C-terminal region of dynAP are known, but antibodies that recognize the N-terminal region of dynAP provided by the present invention can detect dynAP expression in cancer cells with higher sensitivity and accuracy. Can do. More preferably, the diagnostic antibody of the present invention specifically recognizes the amino acid sequence at positions 19-32 of human dynAP represented by SEQ ID NO: 2.
In addition, dynAP is particularly useful in the diagnosis of these cancers because it is particularly frequently expressed in neuroblastoma, prostate cancer and renal cell cancer. Conventionally, there is no report that dynAP is frequently expressed in these cancers. Therefore, the present invention also provides a method for diagnosing neuroblastoma, prostate cancer or renal cell carcinoma, characterized by measuring the expression level of dynAP in a biological sample derived from a subject.
According to the present invention, dynAP has a C-terminal region protruding from the cell membrane. Therefore, for the purpose of detecting a dynAP highly expressing tissue by in vivo administration of an anti-dynAP antibody such as PET diagnosis, an antibody that recognizes the C-terminal region of dynAP is preferable as the anti-dynAP antibody.

  The test method of the present invention using the diagnostic antibody of the present invention is not particularly limited, and the amount of antibody, antigen or antibody-antigen complex corresponding to the amount of antigen in the test sample is chemically or physically determined. Any measurement method may be used as long as it is a measurement method that is detected by means and calculated from a standard curve prepared using a standard solution containing a known amount of antigen. For example, nephrometry, competition method, immunometric method and sandwich method are preferably used.

  The test sample is not particularly limited and includes, for example, a biopsy sample collected from a patient. However, a sample that can be easily collected from a living body such as blood, plasma, serum, saliva, urine, etc. is used within a detectable range. You can also.

As a labeling agent used in a measurement method using a labeling substance, for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance, or the like is used. As the radioisotope, for example, [ ¹²⁵ I], [ ¹³¹ I], [ ³ H], [ ¹⁴ C] and the like are used. The enzyme is preferably stable and has a large specific activity. For example, β-galactosidase, β-glucosidase, alkaline phosphatase, peroxidase, malate dehydrogenase and the like are used. As the fluorescent substance, for example, fluorescamine, fluorescein isothiocyanate and the like are used. As the luminescent substance, for example, luminol, luminol derivatives, luciferin, lucigenin and the like are used. Furthermore, a biotin-avidin system can also be used for binding of an antibody or antigen and a labeling agent.

  For insolubilization of an antigen or antibody, physical adsorption may be used, or a method using a chemical bond usually used to insolubilize or immobilize a protein or an enzyme may be used. Examples of the carrier include insoluble polysaccharides such as agarose, dextran, and cellulose, synthetic resins such as polystyrene, polyacrylamide, and silicon, or glass.

  In the sandwich method, a test sample is reacted with an insolubilized antibody of the present invention (primary reaction), and another labeled antibody of the present invention is reacted (secondary reaction), followed by a labeling agent on an insolubilized carrier. By measuring the amount (activity), the amount of the peptide of the present invention in the test sample can be quantified. The primary reaction and the secondary reaction may be performed in the reverse order, or may be performed simultaneously or at different times.

The monoclonal antibody against the polypeptide of the present invention can also be used in measurement systems other than the sandwich method, such as a competitive method, an immunometric method, or nephrometry.
In the competition method, the antigen in the test sample and the labeled antigen are reacted competitively with the antibody, and then the unreacted labeled antigen (F) and the labeled antigen (B) bound to the antibody are separated ( B / F separation), measure the amount of labeled B or F, and quantify the amount of antigen in the test sample. In this reaction method, a soluble antibody is used as an antibody, a B / F separation is performed using polyethylene glycol, a liquid phase method using a second antibody against the antibody, and a solid-phased antibody is used as the first antibody, or The first antibody is soluble, and the second antibody is a solid phase method using a solid phase antibody.
In the immunometric method, the antigen of the test sample and the immobilized antigen are competitively reacted with a certain amount of labeled antibody, and then the solid phase and the liquid phase are separated, or the antigen and excess in the test sample are separated. Then, the solid phase antigen is added, and then the solid phase antigen is added to bind the unreacted labeled antibody to the solid phase, and then the solid phase and the liquid phase are separated. Next, the amount of label in any phase is measured to quantify the amount of antigen in the test sample.
In nephrometry, the amount of insoluble precipitate produced as a result of the antigen-antibody reaction in a gel or solution is measured. Laser nephrometry using laser scattering is preferably used even when the amount of antigen in the test sample is small and only a small amount of precipitate is obtained.

In applying these individual immunological measurement methods to the quantification method of the present invention, special conditions, operations and the like are not required to be set. What is necessary is just to construct | assemble the measurement system of the peptide of this invention, adding the usual technical consideration of those skilled in the art to the usual conditions and operation methods in each method. For details of these general technical means, it is possible to refer to reviews, books and the like.
For example, Hiroshi Irie “Radioimmunoassay” (Kodansha, published in 1974), Hiroshi Irie “Continue Radioimmunoassay” (published in Kodansha, 1974), “Enzyme Immunoassay” edited by Eiji Ishikawa et al. 53), edited by Eiji Ishikawa et al. "Enzyme Immunoassay" (2nd edition) (Medical Shoin, published in 1982), edited by Eiji Ishikawa et al. "Enzyme Immunoassay" (3rd edition) (Medical School, Showa 62), “Methods in ENZYMOLOGY” Vol. 70 (Immunochemical Techniques (Part A)), ibid. Vol. 73 (Immunochemical Techniques (Part B)), ibid. Vol. 74 (Immunochemical Techniques (Part C)), ibid. 84 (Immunochemical Techniques (Part D: Selected Immunoassays)), ibid. Vol. 92 (Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods)), ibid. )) (Above, published by Academic Press) It is possible to irradiation.

  The cancer therapeutic agent which contains the substance which inhibits the expression or function of said dynAP can be used for the cancer patient determined to be cancer which expresses dynAP by said test | inspection method. Since the therapeutic agent exerts a therapeutic effect depending on the dynAP level in cancer cells, it is important to confirm in advance that the cancer patient to be administered has a cancer that expresses dynAP.

  Examples of the present invention will be described below, but the present invention is not limited to these examples.

[Materials and methods]
1. Plasmid, cell culture and transfection The plasmid used for screening of human cDNA in Saccharomyces cerevisiae was constructed using the Gateway cloning system (Invitrogen). About 10,000 clones on the entry vector were introduced into pYES-DEST52 (Invitrogen). A pcDNA-DEST53 or pcDNA-DEST54 (Invitrogen) based plasmid was constructed using the same system for expression in human cells of dynAP tagged with GFP or V5. Using standard PCR methods, DNA fragments encoding dynAP, Akt1, cyclin D1, Mst1 full-length cDNA, and activated Mst1 (N-terminal 326 amino acids) were subcloned into pFLAG-CMV2 (Sigma), respectively. dynAP, pFLAG-Akt1, pFLAG-cyclinD1, pFLAG-Mst1 Full and pFLAG-Mst1N WT were obtained. A function-deficient Mst1N expression vector (pFLAG-Mst1N KD) was prepared by introducing K59R mutation using pFLAG-Mst1N WT as a template and Quikchange (Stratagene) kit. The Kan / Neo resistance gene of pEGFP-N1 (Clonetech) was amplified by PCR and introduced into pFLAG-CMV2 as a vector for the production of stable expression strains of cyclin D1 and Akt. The stably expressing HeLa cell line was selected in a medium containing G418 at a final concentration of 750 μg / ml. The yeast mutant used in the present invention was derived from the wild type BY4742 strain and was constructed by the Saccharomyces genome deletion project (www-sequence.stanford.edu/group/yeast_deletion_project/project_desc.html). Standard techniques and media were used for budding yeast. Human cell lines: ACHN, Caki-1, CoLo205, DLD-1, Kato III, KB, LNCap.FGC, MCF-7, MKN7, SW480 and WiDr-TC are the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, from Tohoku University; HCC38, HCT-116, MDA-MB-231, MDA-MB-468 and SH-SY5Y from the American Type Culture Collection; A549, HEK293, HT1080, HUC-Fm, KMST-6, NB-1, NH-12, SK-MEL-26, VA-13 and WI-38 are from the RIKEN Bioresource Center; KYSE150, SW13 and U-251MG are from the Japanese Collection of Research Bioresources; Saos2 is R. Takahashi ( From Doshisha Women's College of Liberal Arts); HeLa was each distributed by T. Nishio (Kinki University). Human cells were maintained in RPMI 1640, MEM, DMEM (Nacalai Tesque), MEM-ALPHA or McCoy's 5A (Gibco) supplemented with 10% FCS, 100 U / ml penicillin and 100 μg / ml streptomycin (Nacalai Tesque). For selection of neomycin-resistant cells, 400-750 μg / ml geneticin (Wako) was further added to the above medium. Cells were transfected with the plasmid using Lipofectamine 2000 or LTX (Invitrogen) according to the manufacturer's protocol.

2. Chemical substances Fig. 1 shows the structural formulas of the eight compounds used. Compound # 5 is a Cordyceps fungus Isaria sp. NBRC 104353 (National Institute of Technology and Evaluation (NITE) Biotechnology Headquarters, Biogenetic Resource Division (NBRC), 2-5-Kazusa Kamashichi, Kisarazu City, Chiba Prefecture 292-0818 From the culture extract solution (purchased from No. 8) using the activity as an index. Isaria sp. NBRC 104353 was cultured in a 50 ml test tube containing 15 ml of potato-dextrose medium (24 g / l potato-dextrose; BD Biosciences, San Jose, CA, USA). The test tube was shaken at 27 ° C. for 3 days using a reciprocating shaker (355 rpm). The culture (1 ml) was transferred to a 100 ml Erlenmeyer flask containing solid medium consisting of 3 g oatmeal (Quaker, Chicago, IL, USA) and 10 ml V8 Mix Juice (Campbell Soup Company, Camden, NJ, USA). The culture was stationary at 14 ° C. for 14 days. The culture (20 flasks) was extracted with 80% acetone. After concentration under reduced pressure, the aqueous concentrate was extracted three times with 100 ml of ethyl acetate. The organic layer was dried over sodium sulfate and evaporated to dryness. The dried residue (0.58 g) was subjected to normal phase medium pressure liquid chromatography (MPLC; Purif-Pack SI 60 μm, size: 60, Moritex, Tokyo, Japan) and stepwise with n-hexane-ethyl acetate and chloroform-methanol The active fraction (73.0 mg) was obtained in chloroform-methanol (19: 1) eluate. The active fraction was rechromatographed on normal phase column using chloroform-methanol (99: 1, 49: 1, continuous). Finally, the active fraction (9.5 mg) was separated by reverse phase using Senshu Pak PEGASIL ODS column (20 id × 150 mm; Senshu Scientific, Tokyo, Japan) developed with 80% methanol-water containing 0.1% formic acid. Purification by HPLC (flow rate: 10 ml / min) gave Compound # 5 (3.4 mg, retention time 19.7 minutes).
Compound # 5 was obtained as a colorless amorphous solid (([α] ²⁴ _D + 4.0 °, c 0.12, in MeOH; UV λ240 nm, sh, in MeOH), by HR-electrospray ionization (ESI) -MS The molecular formula was determined as C ₂₈ H ₄₂ O ₆ (m / z 475.3078, theoretical value of C ₂₈ H ₄₃ O ₆ : 475.3060) .The carbonyl group from the IR (ν _max 1714 cm ⁻¹ ) spectrum of compound # 5 The direct bond between each proton and carbon was determined from a heteronuclear single quantum correlation (HSQC) spectrum, and the ¹³ C and ¹ H NMR spectral data of compound # 5 are shown in Table 1.

Other ergostan related compounds were purchased from Sigma (# 4, # 6 and # 7), Nacalai Tesque (# 1 and # 2) and Tokyo Kasei Kogyo (# 3), respectively. Compound # 8 was obtained by treating compound # 6 (0.6 mg) with 1 M sodium hydroxide. After acidification, the crude product was purified by silica gel column chromatography using a gradient of ethyl acetate-hexane (1: 4, 1: 1 and 1: 0) to give compound # 8 (0.5 mg). .
[α] _D +115 (c 0.013, MeOH); CD (MeOH) Δε ₃₀₂ +0.58, Δε ₂₀₁ +5.6; ¹ H NMR (CDCl ₃ , 400 MHz) δ _H 0.62 (3H, s, H ₃ -18) , 0.77 (3H, d, J = 7.0 Hz, H ₃ -21), 0.78 (3H, d, J = 7.0 Hz, H ₃ -26), 0.85 (3H, d, J = 7.0 Hz, H ₃ -27 ), 0.87 (3H, d, J = 7.0 Hz, H ₃ -28), 1.02 (3H, s, H ₃ -19), 2.23 (1H, d, J = 12.1 Hz, H-12), 2.48 (1H , ddd, J = 13.5, 3.5, 3.5 Hz, H-9), 2.52 (1H, d, J = 12.1 Hz, H-12), and 3.57 (1H, m, H-3); HRESITOFMS m / z 439.3559 [M + Na] ⁺ (Calcd for C ₂₈ H ₄₈ O ₂ Na: 439.3552)
Z-VAD-FMK was purchased from BioMol and LY294002 was purchased from Cayman Chemical Co. Compound # 5 and Z-VAD-FMK were dissolved in DMSO, and the other compounds were dissolved in ethanol. When testing the effects of these compounds on cells, the final concentrations of DMSO or ethanol were adjusted to 1% and 0.25%, respectively. Control experiments were performed only with these concentrations of solvent.

3. Anti-dynAP antibody A rabbit polyclonal antibody against a synthetic 14-mer peptide (corresponding to amino acids 19-32 of dynAP) was prepared by consigning to Asahi Glass. The antibody was purified using an affinity column on which an antigen peptide was immobilized. A rabbit polyclonal antibody (HPA011148) against the C-terminal region of dynAP (corresponding to amino acids 143-1210) was purchased from Sigma.

4). Cell extract preparation and immunoblotting Recovered cells were rinsed once with PBS (Sigma) and lysed in lysis buffer (CytoBuster Protein Extract Reagent; Novagen) containing 1 mM PMSF and protease inhibitor cocktail (Nacalai Tesque) . Cell lysates were incubated on ice for 15 minutes and centrifuged at 13,000 xg for 15 minutes.
The following primary antibodies were used: anti-α-tubulin antibody (provided by Dr. Andrea Baines, Sir William Dunn School of Pathology, UNIVERSITY OF OXFORD); anti-caspase-8 antibody and anti-PARP antibody (BD PharMingen); Anti-E-cadherin antibody, anti-p150Glued antibody, anti-dynamitin antibody and anti-GM130 antibody (BD Transduction Laboratories); anti-Mst1 antibody (Cell Signaling Technology); anti-GFP antibody (Roche); anti-V5 antibody (MBL); anti-Akt antibody ( Epitomics Inc.); anti-phosphorylated Akt antibody (Epitomics Inc.); anti-GSK3β antibody (Calbiochem); anti-phosphorylated GSK3β antibody (Epitomics Inc.); anti-β-catenin antibody (MBL); anti-cyclin D1 antibody (Santa cruz) anti-p53 antibody (Santa cruz biotechnology Inc.); anti-p21 antibody (Cell signaling technology); anti-S6K antibody (Epitomics Inc.); anti-phosphorylated S6K antibody (Epitomics Inc.).
HRP-labeled goat anti-mouse or anti-rabbit IgG antibody ((BioSource) was used as the secondary antibody. TrueBlot anti-mouse or anti-rabbit IgG-HRP (eBioscience) should be used if the intensity of the IgG band needs to be reduced. Used as secondary antibody.

5). Co-immunoprecipitation Anti-c-myc antibody (Covance), p150Glued, dynamitin and dynAP, or preimmune serum was preincubated for 2 hours using ExtraCruz IP Matrix (Santa Cruz Biotechnology Inc.). After washing 3 times with lysis buffer, 100-500 μg of cell extract was added and incubated for another 2 hours. The immunoprecipitate was washed 3 times with lysis buffer and subjected to immunoblot analysis.

6). Cell fractionation The method described in J Biol Chem 275: 32482-32490 (2000) was basically followed. About 1 × 10 ⁶ ACHN cells were used. Ultracentrifugation was performed using Himac CS-150GXL (Hitachi) and S140AT rotor.

7. RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. RT-PCR was performed with ReverTra Ace-α (Toyobo) using primers that amplify 0.8 mg of total RNA and full length of dynAP cDNA. GAPDH mRNA was used as an internal standard. The used primers are as follows.
dynAP
5'-ATGGTTGCAGATATAAAGGG-3 '(forward) (SEQ ID NO: 3)
5'-TTATAAATGATCGGTAGGTG-3 '(reverse) (SEQ ID NO: 4)
GAPDH
5'-ACCACAGTCCATGCCATCAC-3 '(forward) (SEQ ID NO: 5)
5'-TCCACCACCCTGTTGCTGTA-3 '(reverse) (SEQ ID NO: 6)
Cyclin D1
5'- CCTCTGTGCCACAGATGTGAAGTTCATTTC -3 '(forward) (SEQ ID NO: 7)
5'- TTAGATGTCCACGTCCCGCA -3 '(reverse) (SEQ ID NO: 8)
E-cadherin
5'-TTGAGCACGTGAAGAACAGC -3 '(forward) (SEQ ID NO: 9)
5'- GGCGTTGTCATTCACATCAG-3 '(reverse) (SEQ ID NO: 10)

8). Immunofluorescence microscopy
Human cells grown on poly-L-Lys-coated glass slides (IWAKI) were fixed with 70% methanol or 3% paraformaldehyde for 10 minutes, 1% BSA and 0.1% Triton X-100 (Nacalai Tesque) Blocked and infiltrated with PBS containing for 30 minutes. Under non-permeating conditions, Triton X-100 was removed from the buffer. The cells were then incubated for 1 hour with antibodies against α-tubulin, β-tubulin (Lab Vision), β-actin, FLAG, GM130 and p150Glued appropriately diluted with buffer. As a secondary antibody, a donkey anti-rabbit or anti-mouse antibody (Jackson ImmunoResearch) labeled with Cy3 or Alexa488 (Invitrogen) was used and diluted for 1 hour with the above buffer. Cy3 labeled anti-V5 antibody was used for staining of dynAP tagged with V5. Finally, the DNA was stained with 4'6-diamidino-2-phenylindole (DAPI). Images were made using an Axioskop 2 plus microscope (Carl Zeiss).

9. Flow cytometry After trypsinization, the cells were centrifuged to a pellet and fixed with ice-cold 70% ethanol. After removing the ethanol, the cells were resuspended in PBS containing 2.5 μg / ml propidium iodide and 0.5 mg / ml RNase A (Nacalai Tesque) and analyzed using JSAN Cell Sorter (Bay Bioscience).

10. Search for dynAP binding partners
Anal Chem 74: 4725-4733 (2002). Extracts prepared from HeLa cells and HEK293 cells that transiently express dynAP tagged with FLAG were immunoprecipitated using anti-FLAG antibody, and then eluted with FLAG peptide. After digesting the eluted protein with Lys-C endopeptidase, the obtained peptides were analyzed using a high-sensitivity direct nanoflow LC-MS / MS method. Sequenced peptides were searched in the database to predict dynamitin as a dynAP binding partner in HeLa and HEK293 cells.

11. shRNA knockdown of dynAP The following sense and antisense oligonucleotides were annealed and cloned into pcDNA 6.2-GW / EmGFP-miR (Invitrogen) to obtain pdynAP_shRNA_1.
Sense: 5'-TGCTGTTGAGCTGCCAGTATCACAAGGTTTTGGCCACTGACTGACCTTGTGATTGGCAGCTCAA-3 '
(SEQ ID NO: 11)
Antisense: 5'-CCTGTTGAGCTGCCAATCACAAGGTCAGTCAGTGGCCAAAACCTTGTGATACTGGCAGCTCAAC-3 '
(SEQ ID NO: 12)
pcDNA 6.2-GW / EmGFP-miR-neg control (Invitrogen) introduced into pcDNA 6.2-GW / EmGFP-miR was used as a control. The obtained plasmid was introduced into HeLa cells by a conventional method, and the cell extract was subjected to immunoblot analysis.

12 Serum Stimulation Cells were cultured in serum-free medium for 24 hours, 10% FBS was added, and 30 minutes later, the cells were fixed with methanol and stained with anti-α-tubulin antibody and anti-β-actin antibody.

[result]
1. Screening for human proteins and low molecular weight compounds using yeast Mutant yeast lacking approximately 10,000 human cDNAs under the control of the inducible GAL1 promoter, Mad2 which is a major regulator of wild-type yeast and spindle assembly checkpoint Introduced. Next, the present inventors investigated a cDNA that inhibits the growth of the mutant yeast but does not inhibit the growth of the wild-type yeast. Among several positive cDNAs, we decided to examine the putative protein encoded by the C18orf26 locus. Expression of this protein (hereinafter abbreviated as dynAP) in mutant yeast lacking other spindle checkpoint factors Mad1, Mad3 and Bub3 showed the same phenotype as Mad2-deficient cells (FIG. 1A). Although the molecular mechanism by which yeast growth is inhibited remains largely unknown, small molecule compounds that can restore dynAP-induced growth inhibition can be candidates for therapeutics as well as dynAP in human cells The present inventors tried to search for such a compound because it would be useful for the research on the function of. That is, in order to obtain small molecules that restore the growth of Mad2-deficient cells expressing dynAP, culture media prepared from fungal and bacterial cultures were screened. As a result, a new ergosterol-related compound (3β, 12β, 14β, 16β) -22,23-epoxy-3,12,14,16-tetrahydroxyergosta-5,7-dien-11-one ( It was named BIR-14; # 5) in Figure 1B was identified. Further investigation of its analogs showed that compounds # 4, # 7 and # 8 were able to restore yeast growth (FIGS. 1B and 1C).

2. Characteristic analysis of dynAP
The nucleotide sequence of the dynAP cDNA predicts an mRNA encoding a 210 amino acid residue protein containing a transmembrane domain (amino acids 113-133) and a threonine rich domain (amino acids 172-207) with a molecular weight of 22.5 kDa (FIG. 2A). ). Amino acid sequence alignments revealed that these domains are highly conserved among mammals (Figure 2B). No homologous genes were found in yeast, flies and nematodes.
Expression of dynAP was tested using a polyclonal antibody against the peptide in dynAP (FIG. 2A) and HeLa cells that stably express GFP-labeled dynAP. The anti-dynAP antibody detected a 70 kDa band corresponding to GFP-tagged dynAP and a 45 kDa band that appeared to be endogenous dynAP, while the anti-GFP antibody also detected a 70 kDa band corresponding to GFP-tagged dynAP. Detected (FIG. 3A). For the commercially available anti-dynAP antibody (HPA011148), a similar experiment was performed using HeLa cells in which FLAG-labeled dynAP was transiently expressed. When this antibody was used, many ladder-shaped bands were observed. Since it was detected and did not match the band pattern of the anti-FLAG antibody, all the newly prepared anti-dynAP antibody that recognizes the N-terminal side was used in the subsequent experiments.
Next, the expression of dynAP in various human cancer cell lines was examined using an anti-dynAP antibody. As a result, of the 40 human cancer cell lines tested, 19 cell lines (47.5%) containing ACHN and HeLa expressed dynAP with a size of 45 kDa (FIG. 3B, Table 2).

  As a result of examining the cancer type specificity of dynAP expression, the medium to high expression rate of neuroblastoma, prostate cancer, and renal cell cancer was 4/4, 3/3, and 2/2, respectively. A small number suggested specific expression (Table 3).

HeLa cells expressed this protein at relatively low levels, whereas other cell lines containing DLD-1 expressed this protein only below the detection limit. Consistent with immunoblot analysis, dynAP mRNA expression was abundant in ACHN and Caki-1 cells, less in HeLa cells, and almost undetectable in DLD-1 cells (FIG. 3C). The size of dynAP (45 kDa) was much larger than expected from its nucleotide sequence. Since SDS-PAGE was performed under reducing conditions, the large size of this dynAP may be due to other post-translational modifications rather than dimer formation via disulfide bonds.
Next, localization of dynAP was examined using HeLa and KMST-6 cells expressing GFP-labeled dynAP. Consistent with predictions based on amino acid sequence, the GFP-tagged protein was localized to the plasma membrane (FIG. 4A). In particular, dynAP was very closely concentrated at the cell-cell boundary. Furthermore, the localization of the GFP-labeled protein overlaps with that of GM130, a Golgi marker protein, indicating that dynAP is highly concentrated in the Golgi membrane around the nucleus (FIG. 4B).
To gain clues about the function of dynAP in cells, we searched for proteins that can bind dynAP by analyzing immunoprecipitates from HeLa and HEK293 cells that express dynAP tagged with FLAG. did. The colocalization of dynAP with β-tubulin and p150Glued was observed (FIGS. 4C and D), consistent with the observation that dynAP interacts with dynactin components as described below. p150Glued is a subunit of the dynactin multiprotein complex that mediates interactions between cytoplasmic dynein motors, microtubules and organelles. Biochemical analysis of intracellular distribution confirmed the microscopic observation that dynAP is a membrane protein (FIG. 4E).
Dynamitin (also known as dynactin 2 or p50) was predicted to interact with dynAP in both cell types. Dynamitin is the main component of the dynactin complex. Dynactin forms a dynein complex and functions as a minus-end-directed microtubule motor that transports intracellular cargo. The interaction between the dynactin complex and microtubules is also necessary to maintain the Golgi apparatus in the perinuclear region. The physical interaction between dynAP and two dynactin components (dynamitin and p150Glued) was demonstrated immunochemically (Figure 5). Co-immunoprecipitation of dynAP and dynactin component was also observed in other cell lines (Figure 6). Since GFP-dynAP co-localizes with p150Glued (see FIG. 4D), it is likely that dynAP is bound to these dynactin components in the cell.

3. Effects of low molecular weight compounds on human cells Next, we tested the effects of selected chemicals on human cancer cells. When ACHN cells were cultured in the presence of compound # 4 or # 8, the number of cells decreased, but other compounds had no effect (FIG. 7A).
Flow cytometry analysis revealed that the sub-G1 fraction, which is an indicator of DNA fragmentation in apoptosis, increased after culturing in the presence of compound # 4 (FIGS. 7B and 8). Procaspase and PARP cleavage are molecular features of apoptotic cell death. Treatment of ACHN cells with compound # 4 or # 8 resulted in cleaved forms of caspase-8 and PARP, which were not detected after treatment with other compounds (FIG. 7C).
To examine whether apoptosis induced by compound # 4 is dependent on dynAP levels, ACHN, HeLa and DLD-1 cells (highly expressed, lowly expressed and very lowly expressed dynAP, respectively, FIG. 3B ) Was treated with compound # 4. The sub-G1 fraction of ACHN cells increased with low dose (5 μM) of Compound # 4, whereas the sub-G1 fraction of DLD-1 cells was very high even with high dose (25 μM) of Compound # 4. It remained low (Figure 7D and Figure 9). HeLa cells were intermediate between ACHN and DLD-1 cells for sensitivity to compound # 4 and correlated well with dynAP levels. Similarly, a close correlation between dynAP levels and sensitivity to compound # 4 was also detected by detecting caspase-8 and PARP cleavage (FIG. 7E). Since staurosporine activated caspase-8 in DLD-1 cells (FIG. 10), the lack of caspase-8 cleavage in these cells is not due to the loss of this apoptotic pathway.
Among the existing molecules involved in caspase-8-mediated apoptosis, we found that compound # 4 causes Mst1 cleavage in ACHN and HeLa cells but not in DLD-1 cells. (Figure 11A). Mst1 is a serine-threonine kinase expressed ubiquitously and has homology with Ste20 of budding yeast. Caspase-mediated cleavage of Mst1 removes the C-terminal regulatory domain, resulting in highly active Mst1. Z-VAD-FMK, an inhibitor of all caspases, attenuated not only caspase-8 and PARP but also Mst1 (FIG. 11B). Procaspase-8 and Mst1 cleavage is stimulated by the expression of GFP-dynAP in HeLa cells (FIGS. 11C and D), whereas when dynAP is knocked down by shRNA, compound # 4 dependent caspase-8 and PARP Was suppressed (FIG. 11E). These results are in good agreement with the hypothesis that dynAP levels make cells more sensitive to compound # 4. Time course experiments showed that cleavage of Mst1 coincides with cleavage of procaspase-8 and PARP (FIG. 11F).
Positioning of the Golgi apparatus around the nucleus is highly controlled by the microtubule cytoskeleton and microtubule motor proteins, including the dynein-dynactin complex. Since dynAP interacts with dynactin components and localizes to the Golgi apparatus, we tested the effect of the above compounds on Golgi positioning. Treatment of ACHN cells with compound # 4 or # 8 resulted in a significant increase in ACHN cells containing scattered Golgi apparatus, but no increase was observed when treated with other compounds (FIGS. 12A and 13A). Consistent with apoptosis induced by compound # 4, Golgi fragmentation was dependent on the expression level of dynAP, with higher expression of dynAP being more sensitive to compound # 4 (FIGS. 12B and 13B).
As a result of the time course experiment, the increase in the number of ACHN cells containing the scattered Golgi apparatus occurred earlier than the HeLa cells, whereas no DLD-1 cells containing the scattered Golgi apparatus were observed (FIG. 12C). ). In particular, Golgi fragmentation reached a maximum within 10 hours, whereas caspase-8 activation was rarely detected within that period, so fragmentation of the Golgi apparatus was induced by compound # 4. It preceded the activation of caspases. A caspase inhibitor (Z-VAD-FMK) inhibited the apoptotic event induced by Compound # 4 (see FIG. 11B), but did not inhibit Golgi fragmentation (FIG. 14). Consistent with the observations above that it occurs before the start.
We also found that p150Glued was phosphorylated after treatment with Compound # 4 in ACHN cells, whereas such an effect was not observed in DLD-1 cells (FIG. 12D). Corresponding to the phosphorylation, the interaction between p150Glued and dynAP disappeared (FIG. 12E). Phosphorylation of p150Glued has been shown to reduce its affinity for microtubules, which may contribute to Golgi fragmentation. The interaction between p150Glued and dynAP may somehow promote the phosphorylation of p150Glued induced by compound # 4, thereby inducing Golgi fragmentation.
We tested two normal fibroblast cell lines (umbilical cord-derived HUC-fm and lung-derived WI-38) and the WI-38VA-13 cell line transformed with SV-40. Normal cells expressed dynAP only at very low levels, while substantial dynAP expression was observed in transformed cells (FIG. 15A). Consistent with observations on cancer cells, normal cells were resistant to compound # 4 for caspase activation and Golgi fragmentation, whereas transformed cells were sensitive to these effects. (Figures 15B, C and D).

4). Mechanism of action of dynAP inhibitors
ACHN, HeLa, and DLD-1 cells were treated with compound # 4 for 24 hr, and the effect of compound # 4 addition on cyclin D1 levels was examined by immunoblotting (FIG. 16A). Decreased cyclin D1 levels were observed in cells undergoing apoptosis (ACHN, HeLa). When HeLa cells were treated under the same conditions (24 hours after addition of compound # 4), decreased Akt / PKB levels involved in cyclin D1 regulation, decreased Ser9 phosphorylation level of Gsk3β phosphorylated by Akt / PKB (Activation of Gsk3β), β-catenin (c-Myc, involved in cyclin D1 transcriptional activation) level thought to be due to Gsk3β activation, c-Myc level decreased (Fig. 16B, Top). Moreover, total RNA was extracted from HeLa cells under the same conditions, and RT-PCR was performed. In fact, transcription of cyclin D1 was suppressed (FIG. 16B, lower panel). Overexpression of activated Mst1 in HeLa cells resulted in attenuated levels of Akt, phosphorylated Gsk3β, β-catenin and cyclin, similar to those treated with compound # 4 (FIGS. 16C and D) . Treatment of a HeLa cell line overexpressed with FLAG-tagged cyclin D1 (FL-cyclinD1) (not subject to β-catenin and Lef / Tcf expression control) with compound # 4 results in only endogenous cyclin D1. FL-cyclinD1 levels also decreased (Fig. 16E), indicating that compound # 4-dependent attenuation of cyclin D1 levels is induced not only by transcriptional repression but also by destabilization of cyclin D1 protein . As a result of examining p53 and p21 levels in HeLa cells treated with Compound # 4, Compound # 4 increased p53 and p21 levels in a concentration-dependent manner (FIG. 16F). p21 accumulation was also induced by overexpression of activated Mst1 (FIG. 16G). These results suggest that the various effects of compound # 4 are brought about by promoting the cleavage and activation of Mst1 by caspases. As a result of examining the transcription level of the E-cadherin gene when ACHN cells expressing high dynAP and HeLa cells expressing low dynAP were treated with compound # 4, compound # 4 attenuated the transcription of the gene. (Figure 16H).
Furthermore, in the dynAP overexpressing HeLa cell line, Akt activation (ser473 phosphorylation is essential for activation) exhibiting an anti-apoptotic effect was observed compared to control HeLa cells (FIG. 17A). In addition, Akt phosphorylation was also enhanced in VA-13 strain in which WI-38 was cancerized with SV-40 (dynAP expression was enhanced in VA-13 strain) (FIG. 17B). On the other hand, when dynAP was knocked down using shRNA, phosphorylation of Akt was suppressed (FIG. 17C). Furthermore, when HeLa cells, ACHN cells and DLD-1 were treated with 10 μM compound # 4, phosphorylation of ser473 disappeared or was remarkably suppressed (FIG. 17D). As a result of examining the cleavage of procaspase-8 and Mst1 when a HeLa cell line stably expressing Akt tagged with FLAG was treated with compound # 4, phosphorylation of Akt was suppressed depending on the concentration of compound # 4. On the other hand, production of caspase-8, PARP and activated Mst1 was promoted (FIG. 17E).
From the above, it was found that the expression of dynAP and the effect of dynAP inhibitor affect the expression and activation of Akt.

5). Cellular response to serum stimulation
When HeLa cells and HeLa cells overexpressing GFP-tagged dynAP were cultured in a medium not containing FBS, dynAP-dependent phosphorylation of Akt was attenuated (FIG. 18A). HeLa cells expressing dynAP fusion proteins with FLAG at the N-terminus and V5 at the C-terminus are fixed with paraformaldehyde and then permeabilized, and the N-terminus of dynAP is recognized. Immunostaining was performed using an antibody and an antibody that recognizes the C-terminus. As a result, the antibody recognizing the C terminus stained cells with or without permeabilization, whereas the antibody recognizing the N terminus stained only when permeabilized (FIG. 18B). Revealed that the C-terminal side was exposed to the outside of the cell. HeLa cells with shRNA knockdown of dynAP are cultured for 24 hours in medium without FBS, or HeLa cells are cultured for 24 hours in medium without FBS containing 25 μM compound # 4, and then 10% FBS is added. When α-tubulin and β-actin were immunostained 30 minutes later, these cells showed cell morphology after serum stimulation compared to HeLa cells not knocked down dynAP or HeLa cells not exposed to Compound # 4. It was found that the return of was delayed (Figures 18C and D).

  By using the method of the present invention, a novel cancer treatment target can be searched, and an inhibitor for the target protein, and thus a candidate compound for a cancer treatment and / or prevention drug can be selected more easily and quickly. be able to. Moreover, the dynAP inhibitor obtained by the method of the present invention is useful as a lead compound for cancer treatment and / or prevention drug development. Furthermore, the novel anti-dynAP antibody obtained in the present invention is useful as a highly sensitive and highly accurate diagnostic agent for cancer.

  This application is based on Japanese Patent Application No. 2010-1604 filed on Jan. 6, 2010, the contents of which are incorporated in full herein.

Claims (23)

  A mutant yeast lacking a cell cycle checkpoint factor and a corresponding wild-type yeast introduced with a nucleic acid encoding a test protein derived from a mammal are cultured to inhibit the growth of the mutant yeast but not the growth of the wild-type yeast. A screening method for a cancer treatment target protein, which comprises selecting a test protein as a candidate for a cancer treatment target protein.   The method of claim 1, wherein the cell cycle checkpoint factor is a spindle assembly checkpoint factor.   The method of claim 2, wherein the spindle assembly checkpoint factor is Mad2.   The method according to any one of claims 1 to 3, wherein the test protein is involved in the growth of cancer cells.   The method according to any one of claims 1 to 4, wherein the mammal is a human.   The cancer cell expressing the selected protein further comprises inhibiting the expression or function of the protein and confirming that the proliferation of the cancer cell is suppressed. The method described.   A mutant yeast lacking a cell cycle checkpoint factor, into which a nucleic acid encoding a cancer treatment target protein obtained by the method according to any one of claims 1 to 6 has been introduced, is cultured in the presence of a test substance. And selecting a test substance that has recovered the growth of the mutant yeast as a candidate for a substance having an anticancer action, and a method for screening a substance having an anticancer action.   The method according to claim 7, further comprising contacting the selected substance with a cancer cell expressing the protein and confirming that the growth of the cancer cell is suppressed.   The method according to claim 7 or 8, wherein the protein is dynAP.   A test substance that contacts dynAP and a protein constituting the dynactin complex in the presence of a test substance, and that inhibits the binding of both proteins is selected as a candidate for a substance having anticancer activity. A screening method for substances having cancer action.   A cell that expresses dynAP and the protein that constitutes the dynactin complex is brought into contact with a test substance, the binding of both proteins is measured by expression of a reporter gene, and the test substance that inhibits the binding is a substance that has anticancer activity A screening method for a substance having an anticancer activity, which is selected as a candidate for   The method according to claim 10 or 11, wherein the protein constituting the dynactin complex is p150Glued or dynamitin.   It has an anticancer activity, characterized by contacting a cell expressing dynAP and p150Glued with a test substance, and selecting a test substance that promotes phosphorylation of p150Glued as a candidate for a substance having an anticancer action. Substance screening method. A cell that expresses dynAP is contacted with a test substance, and a test substance that exhibits any of the following actions (a) to (h) is selected as a candidate for a substance having an anticancer effect: And screening method for substances having anticancer activity.
(A) increase the number of cells containing the scattered Golgi apparatus (b) inhibit Akt expression and / or phosphorylation (c) inhibit GSK3β phosphorylation (d) inhibit β-catenin expression ( e) inhibit the expression of one or more genes selected from cyclin D1, c-Myc and E-cadherin (f) increase the protein level of p53 and / or p21 (g) from Mst1, caspase-8 and PARP Enhances cleavage of one or more selected proteins (h) attenuates cellular response to serum stimulation   15. The method of claim 14, wherein the cell expressing dynAP comprises a reporter gene under the control of a cyclin D1 gene promoter. A therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits expression of dynAP selected from the following (a) to (c).
(A) antisense nucleic acid against RNA encoding dynAP (b) ribozyme nucleic acid against RNA encoding dynAP (c) nucleic acid having RNAi activity against RNA encoding dynAP or precursor thereof A therapeutic or prophylactic agent for cancer expressing dynAP, comprising a substance that inhibits the function of dynAP selected from the following (a) and (b).
(A) Neutralizing antibody against dynAP (b) Compound that inhibits binding between dynAP and the protein constituting the dynactin complex   The agent according to claim 17, wherein the protein constituting the dynactin complex is p150Glued or dynamitin. The agent according to claim 17, wherein the compound that inhibits the binding between dynAP and a protein constituting the dynactin complex is represented by the following formula (I).

Wherein R ¹ , R ² , R ³ , R ⁴ and R ⁵ represent at least one substituent with respect to the ring to which they are attached, and each occurrence independently represents a hydrogen atom, hydroxy group, a halogen, which may have a substituent (C 1 _{-C 6)} alkyl group, which may have a substituent (C 2 _{-C 6)} alkenyl group, which may have a substituent good _(C 3 -C ₆₎ alkynyl group, which may have a substituent _(C 3 -C ₆₎ cycloalkyl group, which may have a substituent _(C 1 -C ₆₎ alkoxy group, An optionally substituted (C ₁ -C ₆ ) alkylthio group, an optionally substituted (C ₁ -C ₆ ) alkylsulfinyl group, an optionally substituted group (C ₁ -C ₆₎ alkylsulfonyl group, an amino group which may have a substituent, a nitro Represents a group, a thiol group or a cyano group;
A solid line and a broken line represent a single bond or a double bond. ) The agent according to claim 18, wherein the compound that inhibits the binding between dynAP and the protein constituting the dynactin complex is represented by the following formula (II).

(In the formula, a solid line and a broken line represent a single bond or a double bond.) A compound represented by the following formula (III).
  A diagnostic agent for cancer expressing dynAP, comprising an antibody that recognizes the N-terminal region of dynAP.   The agent according to any one of claims 16 to 20, which is used in combination with the diagnostic agent according to claim 22.